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ABSTRACT
Functional Profiles of Growth Related Genes during Embryogenesis and Postnatal
Development of Chicken and Mouse Skeletal Muscle
Hakan Kocamis
Myostatin (also known as growth differentiation factor/8), a recently identified
member of the TGF-β family, has been shown to negatively regulate skeletal muscle
growth. Activins, also members of the TGF-β family, and their binding protein,
follistatin, once thought to be restricted to reproductive cycle function are in fact involved
in the development of a wide variety of embryological and adult tissues, particularly
skeletal muscles. Reverse-transcription ploymerase chain reaction (RT-PCR) was
performed to measure the ontogeny of myostatin, activin-B, and follistatin gene
expression during chicken embryonic development. Strong myostatin expression was
found in the early chicken embryos (E 0, E 1) and the developmental expression pattern
of myostatin mRNA coincided with the periods of primary and secondary muscle fiber
formation. Follistatin transcripts followed a linear expression pattern from E 0 to E 20,
while activin-B had a quadratic pattern.
The ontogeny of myostatin gene expression was nearly identical in satellite cells
isolated from pectoralis major (PM) and biceps femoris (BF) muscles of chicken.
Activin-B mRNA level in PM satellite cells was higher than in BF satellite cells at 72 h
and 120 h (P < 0.01), whereas levels in BF satellite cells were higher than in PM satellite
cells at 96 h and 144 h (P < 0.01). Amounts of follistatin mRNA in PM satellite cells
were higher than in BF satellite cells at 24, 96, and 120 h of culture (P < 0.01). No IGF-I
gene expression was detected in either cell culture at any time point in the present study.
IGF-II mRNA level plateaued in PM satellite cells by 48 h after plating (P < 0.05), and
remained elevated until 144 h of culture. In ovo administration of rhIGF-I at E 3 altered
myostatin, follistatin, activin-B, and TGF-β2 gene expressions during chicken embryonic
development with emphasis on skeletal muscle development. Myostatin mRNA from
pectoralis muscles of rhIGF-I injected embryos increased on E 10 (~ 2.5 fold) and
remained high through E 13, whereas mRNA from control pectoralis muscles increased
at E 9 and remained high until E 12.
IGF-I, -II and IGF receptor-I mRNA and protein levels were determined in a wide
variety of myostatin knockout mice tissues. IGF-I mRNA levels were not different
between control and knockout mice tissues, whereas levels for IGF-II were significantly
higher in myostatin knockout mice kidney and soleus muscles than that of control mice
(P < 0.01). IGF-Receptor-1 mRNA levels from control mice heart (P < 0.05) and kidney
(P < 0.01) were significantly higher than that of myostatin knockout mice, while levels
were lower in control mice pectoralis muscle than that of knockout mice (P < 0.01). The
strongly IGF-II positive cells were more common in myostatin knockout mice and were
seen in a few foci in control mice, while no consistent differences in IGF-II
immunoreactivity were detected between the two groups of mice kidneys.
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INTRODUCTION

A series of defined cellular events orchestrates the development of skeletal
muscle. First, mesodermal cells become epithelized and partitioned into the somites
(Christ et al., 1983). Dorsal parts of the somites form the dermomyotome, which
ultimately gives rise to the dermis and skeletal muscle of the back, body wall and limbs
(Ordahl and Le Douarin, 1992). Then, myoblasts undergo terminal differentiation to
myocytes expressing contractile proteins characteristic of skeletal muscle (Cusella-De
Angelis et al., 1992). Finally, myocytes align and fuse to form multinucleated myotubes.
Sequential myofiber formation establishes the muscle groups. Primary myofibers, which
form from the first wave of myoblasts, are the first to arrive at the premuscle mass, while
secondary fibers, which are late migrating myoblasts, develop around the primary fibers.
It has been suggested in chickens that the myoblast withdrawal process is biphasic,
starting at embryonic day (E) 7 (primary myofibers), then stopping, and starting once
again around E 11 (secondary myofibers) (O’Neill, 1987). The ratio of terminally
differentiated myocytes in the embryonic breast and thigh muscles increases from a few
percent at E 7 to 80% at E 18 (O’Neill, 1987). The schematic presentation of key
myogenic events during chicken embryonic development is provided in the Appendix of
this dissertation.
The precise mechanisms that control the events converting somites to functional
muscle remain largely unknown. Nevertheless, based on recent in vitro findings and
advances in developmental biology techniques, it has been suggested that growth factors
such as, insulin-like growth factors (IGFs), transforming growth factor betas (TGF-βs),
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and fibroblast growth factors (FGFs) play a significant role in coordinating these
processes. Particularly, myostatin (also known as growth differentiation factor/8), a
recently identified member of the TGF-β family, has led scientists to reevaluate their
concepts about muscle development in vertebrates. Based on the observations obtained
from myostatin knockout mice that displayed a marked increase in muscle mass, up to
three times normal size (McPherron et al., 1997), myostatin has been proposed to be a
negative regulator of skeletal muscle growth. Additionally, activins, also members of the
TGF-β family, and their binding protein, follistatin, once thought to be restricted to
reproductive cycle function are in fact involved in the development of a wide variety of
embryological and adult tissues, particularly skeletal muscles. Therefore, myostatin,
activin, and follistatin expression and their biological functions are reviewed in the
following section.
LITERATURE REVIEW
MYOSTATIN
How is the size of an animal determined? Most importantly, how is the growth of
an individual tissue controlled to reach and maintain its proper size? These questions
remain as mysterious as ever.
There has to be a mechanism to coordinate the growth of each tissue so that they
can produce harmony in the whole organism. Several theories have been suggested to
explain this phenomenon. The most favored by scientists in the field of growth biology is
that each tissue produces an inhibitor that specifically suppresses the growth of itself
(Bullough, 1962). As the organ or tissue grows, the inhibitory substance accumulates
until it reaches a threshold causing cessation of growth of the tissue or organ from which
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it was produced (Goss, 1978). This theory can relate to liver regeneration as described as
early as in ancient Greek mythology (for review, see McPherron and Lee, 1999) and in
grafting experiments. For instance, the removal of part of the liver causes rapid
compensatory growth of the remainder. Also, when a small liver is transplanted to a large
host, it will grow much faster than the normal rate until it has reached proportional size of
the host (Kam et al., 1987). Because of the lack of direct evidence for tissue specific
inhibitory molecules, this once-widely-accepted theory fell out of favor. However, based
upon recent findings, this type of mechanism can operate in skeletal muscle growth.
When myostatin (also known as growth and differentiation factor/8), a member of TGF-β
family, was disrupted in mice, muscle mass increased up to three times normal size
(McPherron et al., 1997). Additionally, myostatin mutation has been linked to double
muscled cattle breeds (Grobert et al., 1997, Kambadur et al., 1997). It is, therefore,
suggested that myostatin is the negative regulator of muscle growth in normal animals.
Myostatin Structure and Expression
Myostatin is mainly synthesized in skeletal muscle as a 376 a.a. propeptide, which
gives rise to 15 kDa active, processed and mature protein (McPherron et al., 1997).
Structurally, it contains all the characteristic features of the TGF-β family, such as a
proteolytic processing signal site and an active carboxy-terminal region that has the
highly conserved patterns of cysteine knots (McPherron et al., 1997). The a.a. sequence
of the active, proteolytically-processed carboxy-terminal site of myostatin has 100%
homology among murine, rat, human, porcine, chicken, and turkey species (McPherron
and Lee, 1997), which suggests a common and highly conserved function.
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Myostatin was detected very early in the myotome of developing mouse (McPherron et
al., 1997) and cattle embryos (Kambadur et al., 1997) and expression continued in the
adult muscle. It was located in the cytoplasm of muscle fibers and was absent from
connective tissue (Kirk et al., 2000). Myostatin protein level was higher in the slowfiber-type dominated muscles (soleus) than in the fast-fiber-type dominated muscles
(tibialis anterior) of rats (Sakuma et al., 2000). On the contrary, myostatin mRNA and
protein level were higher in fast-fiber-dominated muscles (gastrocnemius/plantaris) than
in slow-fiber-dominated muscles (soleus) of mice (Carlson et al., 1999) and rats (Wehling
et al., 2000). In humans, there was no difference between fast-fiber-dominated and slowfiber-dominated muscles in terms of their myostatin gene expression (Gonzalez-Cadavid
et al., 1998). In chicken satellite cells isolated from pectoralis major (predominantly fast
fibers) and biceps femoris (predominantly slow fibers) muscles, myostatin mRNA
expression was nearly identical (Fig. 1) with the exception of significant increase when
fusion started in biceps femoris satellite cells (Kocamis et al., 2001). Despite the various
results among the species, myostatin may be one of the major determinants of muscle
fiber type in any given muscle. On the other hand, myostatin expression is not certainly
limited to skeletal muscle tissues. For instance, its expression was detected in
cardiomyocytes and purkinje fibers of cattle heart (Sharma et al., 1999), and in adipose
tissue and tubuloalveolar secretory lobules of lactating mammary glands in pigs (Ji et al.,
1998).
How Myostatin Functions
Myostatin knockout mice demonstrated a dramatic and widespread increase in
skeletal muscle mass due mainly to increase in the number of muscle fibers (hyperplasia)
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and also the thickness of the fibers (hypertrophy), irrespective of age and sex of animals
(McPherron et al., 1997). In addition, some of the double muscled cattle breeds
(discussed below) have been found to possess loss of function mutations in the myostatin
coding sequence (Kambadur et al., 1997, Grobert et al., 1997).
It is well known that the size of any given tissue depends on the number and size
of the cells it contains as well as on the amount of extracellular matrix and fluid (for
review, see Conlon and Raff, 1999). Cell division and cell death determine appropriate
cell number in a tissue at any time during development. Also, both cell number and cell
size in a tissue depend on interaction between intracellular programming and
extracellular signaling. Currently, it is not known whether myostatin is present in
circulation of any vertebrate. Thus, we will ignore any possible endocrine functions of
myostatin. To increase hyperplasic myoblast growth, myostatin must be acting either by
interrupting normal myoblast cell cycles through changing the activity and/or amount of
regulatory enzymes and/or other components, or by preventing apoptosis. In vitro studies
demonstrated that recombinant myostatin inhibited the proliferation of C2C12 myoblasts
and bovine myoblasts derived from 160-day-old fetuses (Thomas et al., 2000). It was
shown that the inhibitory effect of myostatin was reversible, as myoblasts maintained
their ability to proliferate after it was removed. Extra myostatin specifically upregulated
P21, a cyclin-dependent kinase inhibitor, and decreased the amount of cyclin-dependent
kinases (especially cdk2), a family of enzymes that catalyze events required for cell cycle
transition, in C2C12 cells (Thomas et al., 2000, Rios et al., 2001). Both groups suggested
that myostatin blocked the myoblast transition in the G1/S and/or G2/M phases of the cell
cycle. On the other hand, they found conflicting results in terms of myostatin effects on
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apoptosis, even though they used the same myoblast cell culture. For instance, Thomas
et al. (2000) demonstrated that myostatin did not affect apoptosis in C2C12 cells as
shown in TUNEL assays, whereas Rios et al. (2001) showed that myostatin
overexpression inhibited apoptosis in the same cells. Therefore, further studies should be
conducted to better understand myostatin involvement in apoptosis.
Myostatin dominant negative mice expressing 23-40% less active myostatin due
to the lack of its normal cleavage site, showed widespread hypertrophic muscle growth
but not hyperplasia (Zhu et al., 2000). Muscle hypertrophy in these mice was not due to
the pathways that involve well established transcription factors such as myogenin,
GATA-2, and MEF-2C. Because myostatin knockout mice (fully null for myostatin)
demonstrated both hyperplasic and hypertrophic muscle growth, it is possible to postulate
that the hypertrophic function of myostatin is independent of its hyperplasic functions.
On the other hand, less inhibition of myostatin may be sufficient for hypertrophy,
whereas complete or greater inhibition may be required for hyperplasia.
Experiments with muscle atrophy and mechanically-induced hypertrophy were
conducted to address the possible myostatin function in hypertrophy of fibers of fully
differentiated muscle. Muscle atrophy caused by either hindlimb unloading (Wehling et
al., 2000, Carlson et al., 1999) or by denervation (Sakuma et al., 2000) increased
myostatin mRNA and protein level. These observations were supported by findings of
Gonzalez-Cadavid et al.(1998) who demonstrated that myostatin protein level increased
in the muscle of HIV-infected patients undergoing weight loss. On the contrary,
myostatin protein level was also increased in mechanically-hypertrophied rat muscles. As
widely accepted, mechanical overloading does not induce new fiber formation (Gollnick
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et al., 1981), but appears to promote the hypertrophy of originally present muscle fibers
by stimulating DNA synthesis. However, recombinant myostatin inhibited DNA and
protein synthesis without affecting protein degradation in C2C12 cells (Taylor et al.,
2001) and also myostatin mRNA level was not altered in hypertrophied C2C12 myotubes
transfected with IGF-I (Semsarian et al., 1999). The exact mechanism of myostatin
function in hypertrophy, thus, remains to be elucidated in further studies.
Hypertrophic growth is associated with satellite cell replication in order to
maintain constant nuclear number (Snow, 1990). However, little attention has been paid
to involvement of myostatin in the process of satellite cell proliferation and
differentiation. Myostatin mRNA was detected in satellite cells isolated from chicken
pectoralis major and biceps femoris muscles during proliferation (Fig. 1, Kocamis et al.,
2001). Also, it increased during differentiation of either satellite cell culture, thus
myostatin may be one of the major determinants of satellite cell activation to maintain
overall postnatal muscle mass in vertebrates.
Myostatin in Double Muscling
Double muscling, also known as muscle hypertrophy (mh), is a phenotype
recognized as early as the 19th century, characterized by a visible, generalized increase in
muscle mass due primarily to hyperplasia and is present in Belgian Blue, Piedmontese
and Asturiana de los Valles cattle breeds. These animals have higher birth weights and
also lower fat and bone percentages compared to non-double muscled animals (for
review, see Arthur, 1995). Comparative mapping analysis between human and bovine
genomes led to identification of the mh locus underlying double muscling (Charlier et al.,
1995). However, none of the genes identified within this locus was considered to be a
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strong candidate for the double muscle phenotype, until the study of myostatin knockout
mice was published (McPherron et al., 1997). Location of the myostatin gene was found
to be in mh locus of cattle chromosome 2 by mapping with genetic markers (Smith et al.,
1997, Casas et al., 1999). Given the phenotype of the myostatin knockout mice and
location of myostatin on cattle chromosome 2, the question was if myostatin was the mh
gene. Disruption in the timing, distribution, level of expression or function of the protein
should be the cause of double muscle phenotype in cattle. Because no difference was
found between double muscled and normally muscled cattle embryos or their adult
muscles in terms of timing or level of expression (Kambadur et al., 1997, Grobert et al.,
1997), mutations at the protein level were likely responsible for the phenotype in these
breeds. Indeed, three independent studies, almost concurrently, demonstrated that double
muscled Belgian Blue, Piedmontese and Asturiana de los Valles breeds had mutations in
their myostatin genes (Grobert et al., 1997, Kambadur et al., 1997, McPherron and Lee,
1997). For instance, Belgian Blue cattle have an 11 base pair deletion in the myostatin
gene, resulting in a translational frame shift which causes functional loss. The South
Devon cattle breed has the same mutation in their myostatin gene, but they are not
considered as true double muscled animals (Smith et al., 2000). Additionally, Limousin
and Blonde D’Aquitaine cattle breeds do not demonstrate an observed double muscling
phenotype, although a functional myostatin mutation was found in these animals (Grobert
et al., 1998). Based upon all of these results, the function of single major gene may not
completely explain the double muscling phenotype.
The negative aspects of double muscled phenotypes are calving difficulties, and
smaller internal organs (Arthur, 1995). Interestingly, cattle with only one functional copy
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of the myostatin gene (+/-) had a significant increase in muscle growth, while having a
lower incidence of calving difficulties than homozygous animals (-/-) (Casas et al., 1999).
These findings sharply contradict with the situation in mice, which show little difference
between wild type (+/+) and heterozygous (+/-) animals in muscle weight (McPherron et
al., 1997). Cattle, because of extensive selection for large muscle mass, unlike mice, may
have associated genetic changes that allow for increase in muscling in a heterozygous
animal. Genetic background may be critical in determining the phenotypic response to
myostatin mutations.
Leg weakness (such as twisted leg, chondrodystrophy, and tibial
dyschondroplasia) continues to be a serious problem among meat-type poultry,
particularly with selection for increased body weight gain (Cook et al, 1984). Despite the
extensive muscle growth of the myostatin knockout mouse, its femora were not altered in
either shape or size (Hamrick et al., 2000). It is imperative to note that body weight of the
myostatin knockout mouse was identical to the wild-type control, while it had extreme
muscle growth. Thus, ablation of myostatin during chicken embryonic development may
prevent chickens from having weight-associated skeletal abnormalities, while increasing
muscle mass.
Although the phenotype of myostatin deficient animals allows the possibility that
myostatin may be the specific growth inhibitor that was speculated in the early 1960’s
(Bullough, 1962), several questions remain to be elucidated in terms of exact mechanisms
of myostatin function. First, does myostatin circulate in the blood of any given animal? If
so, do binding proteins in the TGF-β family such as follistatin and noggin regulate its
activity in circulation? Second, does myostatin have a specific receptor or does it use a
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common TGF-β family receptor? Third, can myostatin inhibit the growth of skeletal
muscle in adult animals? If so, is it dose-dependent? Fourth, is myostatin involved in
highly muscled callipyge sheep (Cockett et al., 1994) or Pietrain pigs (Brenig and Brem,
1992)? Fifth, how does myostatin interact with the growth factors that have been well
documented to stimulate skeletal muscle growth, such as insulin-like growth factors
(IGF-I and IGF-II)? Therefore, complete understanding of the biochemistry and
physiology of myostatin could be beneficial to human health and food animal agriculture.
ACTIVINS and FOLLISTATIN
Activins Structure and Expression
Activins were first found in 1986 as a novel protein purified from ovarian
follicular fluid (Vale et al., 1986). They are categorized as members of the TGF-β family
and are present as a dimeric polypeptide linked by one disulfide bond between residue 80
of the mature subunits (Vale et al., 1986). Activins are comprised of homodimers (βAβA
or βB βB) or heterodimers (βAβB), resulting in activin-A, -B and –AB, respectively (for
further review, see DePaolo, 1997). Recently, three more activin subunits (βC, βD, βE)
were found in humans but their functions remain unknown (Hotten et al., 1995, Fang et
al., 1996). Inhibins, which are structurally related to activins, are also dimeric proteins
comprised of an α subunit and one of the two β subunits (βA or βB), thus existing in two
forms αβA or αβB. Southern blot analysis has shown that activin subunits are encoded
by different genes and that they are present as single copies in the human genome
(Thompson et al., 1994, Feng et al., 1989). Additionally, these subunits are very
conserved among the species in terms of genetic organization (Thompson et al., 1994,
Feng et al., 1989).
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Activins are ubiquitously expressed in a wide variety of embryonic and adult
tissues. For instance, they were detected in human as well as rat embryo and adult
nervous system, bone marrow, reproductive tissues, spleen, liver, heart, muscle, and
salivary glands (Ying et al., 1987). Activin mRNAs were also uniformly distributed at the
blastula and gastrula stages of xenopus embryos (Dohrmann et al., 1993). In the chicken,
activin transcripts were first detected during the period of axial mesoderm formation
(Mitrani et al., 1990).
Follistatin Structure and Expression
Follistatin is present as a monomeric polypeptide subject to post-translational
modification resulting in different molecular weights of bioactive proteins (ranging from
31 to 42 kDa) (Robertson et al., 1987). Sequence analysis demonstrated that the
follistatin gene consists of six exons separated by five introns (Shimasaki et al., 1988).
This single follistatin gene is subject to alternative splicing, which in turn gives rise to
follistatin 288 (FS 288) and follistatin 315 (FS 315) in humans (Inouye et al., 1991).
However, analysis of native porcine follistatin failed to detect intact FS 315.
Follistatin is broadly distributed in embryonic and adult tissues and is not
confined to reproductive tissues. It is also present in the circulatory system and binds to
activin via their β subunits (Patel, 1998). Follistatin was first seen during gastrula stages
of xenopus embryos (Matzuk et al., 1995). Follistatin-activin coexpression in developing
mouse kidneys, salivary glands, liver, heart and skeletal muscle was observed.
Additionally, follistatin demonstrated an expression pattern parallel to that of activins,
implying that the activin-follistatin system may act locally and at multiple sites during
early development (Matzuk et al., 1995).
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In chickens, follistatin was first detected in the cranial segmental plate mesoderm
and subsequently in all somites (Ampthor et al., 1996). Within somites, its expression
was localized to the dorso-lateral part of the somites, which give rise to skeletal muscle of
body walls, and limbs (Christ, 1977, Ordahl and Le Dourarin, 1992). Then, expression of
follistatin was detected in myotomes and migrating myogenic cells (Ampthor et al.,
1996). Taken together, follistatin gene expression in chicken somites follows a pattern
suggestive of a role in regulating muscle development (Connolly et al., 1995).
Activin Receptors
The presence of activin membrane surface receptors was first reported in the late
1980s (Sugino et al., 1988). Since then, four types of activin receptors (type-I, -IB, -II
and -IIB) have been identified (Ying et al., 1997). Although they are ubiquitously
expressed in a wide variety of embryonic and adult tissues, some isoforms have been
found to be expressed only in embryos and certain cell types. For instance, type-II activin
receptors were expressed in the embryonic pituitary glands of rats, while only activin
receptor type-IIB was found to be expressed in the adults (Roberts and Barth, 1994).
Activins bind to constitutively activate type-II serine/threonine receptors, but can
not interact with the intracellular signaling components of pathways without recruiting
type-I receptors to the activin-type-II complex (Wrana et al., 1994). Type-I receptors,
unlike type-II receptors, do not bind activins without the presence of type-II receptors
(Ebner et al., 1993, Attisano et al., 1993). Therefore, activins must first bind to type-II
receptors, thereafter type-I receptors are recruited to the complex and become
phosphorylated, then this heteromeric complex initiates intracellular signal transduction
pathways. To form this heteromeric complex, activin binds to each receptor through its β
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subunits (Xu et al., 1995). Thus, when inhibins that have the same β subunits as activins,
bind to type-II receptors, they can not assemble the heteromeric complex due to the lack
of a second β subunit in their structure. Additionally, even though activin type-II
receptors are structurally similar to the TGF-β type-II receptors, TGF-βs do not bind to
these activin receptors (De Winter et al., 1996).
It was recently demonstrated that some of the xenopus and zebrafish embryonic
and adult tissues contain a pseudoreceptor named BAMBI (BMP and activin membranebound inhibitor) (Onichtchouk et al., 1999). It has a type-I receptor-like structure but
lacks a full intracellular domain and thus, can not be phosphorylated. However, BAMBI
can compete with full-length activin type-I receptor to form a heteromeric complex with
activin ligand, thereby inhibiting the potential for signal transduction. Given the fact that
activins have multiple effects on a variety of reproductive and non-reproductive tissues
and that the amount of ligand required for proper response varies among tissues during
development (for details see below), many isoforms of activin receptors and the presence
of pseudoreceptors should be necessary to maintain desired physiological responses.
Biological Functions of Activins and Follistatin
Activins have been proposed as potential local hormones in the regulation of
gonadal cell growth and differentiation as well as follicle stimulating hormone (FSH)
synthesis and secretion. Therefore, the majority of activin and follistatin studies have
been focused primarily on reproductive tissues. For instance, in the absence of follistatin,
activins stimulated the synthesis and secretion of FSH, while simultaneously suppressing
the secretion of growth hormone, prolactin, and adrenocorticotrophic hormone (ACTH),
thereby enabling the organism to enter the reproductive phase. On the contrary, in the
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presence of follistatin, activins were not able to allow the organism to enter the
reproductive phase. Because it is not the intention of this review to cover all of the
biological functions of activins and follistatin in reproductive tissues, two excellent
reviews are recommended (Knight, 1996, DePaolo, 1997).
The phenotype of subunit knockout mice has demonstrated that each activin has
its own function on different tissues. For instance, βA subunit knockout mice lacked
whiskers and lower incisors and had cleft palates, while βB subunit knockout mice
showed distinct developmental and reproductive defects as well as severe eye lesions
(Vassalli et al., 1994). Double knockout mice for βA and βB demonstrated individual
defects of the subunits without any additional defects (Matzuk et al., 1995), implying that
the absence of one subunit is not compensated by another subunit. Follistatin knockout
mice were much smaller than their heterozygous litter mates and had declined mass of
diaphragm, pectoral, and intercostal muscles (Matzuk et al., 1995). These mice failed to
breathe and died soon after birth. They also displayed some skeletal abnormalities as
well as defects of their teeth and whisker development. Follistatin knockout mice
demonstrated a much wider range of improper development than activin knockout mice,
indicating that follistatin may function in a wide range of tissues and that it may also be
involved in the regulation of other TGF-β family members. Additionally, follistatin
transgenic mice did not die at birth and were of normal size (Guo et al., 1998). However,
because males had smaller testes and females had smaller ovaries and uteri, their fertility
rates were reduced.
Recently, many studies have demonstrated that activins and follistatin play a
pivotal role in the induction of mesoderm and neural tissues of embryos. For example, in
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xenopus embryos, addition of extra activins stimulated mesodermal tissue formation
(Thomsen et al., 1990). At high dosage, embryos even displayed a rudimentary axial
pattern and head structure. Furthermore, a dominant negative receptor for activins
blocked the mesoderm formation in these embryos (Hemmati-Brivanlou et al., 1992).
Based on these findings, it is possible to postulate that endogenous activins regulate
mesodermal patterning. On the other hand, overexpression of follistatin in early xenopus
embryos did not block mesoderm induction, while inducing neural tissue formation
(Sculte-Merker et al., 1994).
Activins induced cardiac myogenesis in in vitro chicken embryonic epiblasts
(stage 11 or 15, embryonal days 2 and 2.5 day, respectively) (Ladd et al., 1998).
Addition of follistatin in the medium of these cultures inhibited activin induced cardiac
myogenesis. Furthermore, recombinant human activin A inhibited differentiation in 11
day-old chicken embryonic pectoralis muscles in culture, while recombinant human
follistatin stimulated muscle cell differentiation (Link and Nishi, 1997). Also, myotubes
that were formed in the presence of activin had fewer nuclei and lacked parallel
alignment. On the other hand, cultures grown with follistatin had thicker myotubes that
were aligned in parallel fashion. The inhibitory action of activin on those myoblasts was
distinct from FGFs and TGF-βs (Link and Nishi, 1997). For instance, either TGF-β or
FGF delayed the onset of muscle differentiation, but unlike activin treated cultures, these
cultures eventually reached the control creatine kinase levels, indicative of myotube
maturation. Additionally, activin treated cultures had consistently lower myoD and
myf5 mRNA levels than untreated controls. However, follistatin treated cultures had a
decrease in myoD levels and an increase or no change in myf5 levels compared to
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controls, indicating that the actions of follistatin are not simply reciprocal to those of
activins.
The aforementioned in vivo and in vitro functions of activins and follistatins leads
to the question of how follistatin and activin interact or regulate each other’s action at
either the cellular or endocrine levels. Because both activins and follistatins are present
in circulation, it is assumed that they function as classic endocrine regulators. At the
cellular level, two theories have been suggested. The first is that follistatin captures
activins and sequesters them in the cell matrix as a reservoir for future signaling, so that
follistatin would prevent rapid clearance of activins (Nakamura et al., 1991). Second,
and the most acceptable theory, is that follistatin bound to the cell surface allows
degradation of activins by internalizing the activin and follistatin complex into the cell, so
that follistatin actually facilitates clearance of activins (Hashimoto et al, 1997).
Because no follistatin specific receptor has been found, follistatin has been shown
to have a high affinity for cell surface proteoglycans (particularly heparin sulfates). One
of the major roles of these proteoglycans is to immobilize or sequester growth factors, so
that their actions can be facilitated (Ruoslahti and Tamaguchi, 1995). Although the
affinities of two major forms of follistatin (FS 315, FS 288) for activins are almost
identical (Mathews and Vale, 1991), the FS 288 form of follistatin has greater affinity for
heparin sulfate proteoglycans than FS 315 form (Sugino et al., 1993). Therefore, the
greater effect of FS 288 to suppress FSH secretion has been attributed to greater affinity
of this follistatin form for heparin sulfates.
Given the fact that their multifactorial control mechanism, it is difficult to pin
point what the exact nature of follistatin-activin interaction is in non-reproductive tissues
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such as skeletal muscles. For example, how does follistatin interact with other well
known growth factors such as IGFs in skeletal muscle development? Also, do activins
and follistatin function in the same fashion among several different non-reproductive
tissues such as bone, adipose tissues?
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Chapter 1.

THE ONTOGENY OF MYOSTATIN, FOLLISTATIN AND ACTIVIN-B MRNA
EXPRESSION DURING CHICKEN EMBRYONIC DEVELOPMENT

(Published in: Kocamis et al., 1999. Growth, Development and Aging 63: 143-150)
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INTRODUCTION

Myostatin is a member of the transforming growth factor-β superfamily (TGF-β)
(McPherron et al., 1997). The main source of myostatin synthesis and secretion is skeletal
muscle tissue (McPherron et al., 1997). Myostatin null mutation mice showed a dramatic
increase in skeletal muscle mass, primarily due to an increased number of muscle fibers
(McPherron et al., 1997, McPherron and Lee, 1997). The “double muscle” phenotype of
two breeds of cattle (Belgium Blue and Piedmontese) also has been linked to five
different myostatin gene mutations (Grobert et al., 1998); however, the developmental
pattern of myostatin gene expression in chicken embryos has not been elucidated.
Therefore, one of the objectives was to establish the ontogeny of myostatin gene
expression during chicken embryonic development, with emphasis on skeletal muscle
development.
Activins which are members of the TGF-β superfamily are covalently linked
dimers of two distinct β subunits, thus existing in three different forms, activin-A, AB,
and B (Ying, 1987). Activins and their receptors (type-I and type-II serine/threonine
kinase) are ubiquitously expressed (Tuuri et al., 1994). Activins have multiple biological
effects in a wide variety of reproductive and non-reproductive tissues. Follistatin is a
monomeric glycosylated protein present in several isoforms (for reviews, see Refs.
Michel et al., 1993, Ying et al., 1997, Patel, 1998) and is also expressed ubiquitously
(Tuuri et al., 1994). Most, if not all, of the biological actions of activins are neutralized
by its binding to follistatin (Michel et al., 1993). Furthermore, follistatin binds to inhibins
with less affinity, but the physiological relevance of biological activity of inhibin bound
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to follistatin has not been fully explained. Additionally, the antagonistic actions of
follistatin may extend to other TGF-β family members such as, bone morphogenic
proteins (BMP) (Ampthor et al., 1996).
The expression and regulation of follistatin in the somite and hindbrain of early
chick embryos have been reported (Ampthor et al., 1996, Graham and Lumbsden, 1996).
Furthermore, the follistatin gene in early somites is expressed in a way which suggests
regulation of skeletal muscle development (Ampthor et al., 1996). Beyond these
developmental stages mentioned above, follistatin and activins gene expression as related
to skeletal muscle development in the chicken has not been fully elucidated. Therefore,
the present study expands on the previously published studies by examining the
expression of the follistatin and activin-B gene as well as myostatin in the whole embryo
and pectoralis muscle of the developing chicken embryo.
MATERIALS AND METHODS
Tissue collection
Fertilized eggs (Cobb X Cobb) were obtained from Wampler-Longacre
(Moorefield, WV). Embryos and tissues were harvested in compliance with an approved
West Virginia University Animal Care and Use Committee Protocol. All the embryos
were isolated and washed free of yolk, albumen and extra-embryonic membranes by
sterile nuclease-free water and were staged according to Hamburger and Hamilton,
(1951). Whole embryos were collected on each of the embryonic days (E) 0 to 6 (starting
stage 1 to stage 29, n= 6 per day). Thoracic/abdominal halves of the embryos between
lumbo-sacral level to neck without head were collected on each of E 7 and E 8 (stage 31
and stage 34, respectively, n= 6 per day). Pectoralis muscle was collected on each of E 9
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to E 20 (n= 4 per day). All the tissue collections were performed at consistent times for
each sampling day throughout the experimental period, starting day 9, stage 35, and every
24 h until day 20, stage 45 (Hamburger and Hamilton, 1951).
RNA extraction
Total RNA was extracted from all of the tissues mentioned above using the TriReagent (Sigma) modification of the guanidine isothiocyanate/phenol-chloroform method
as described by Chomczynski and Sacci (1987). The RNA concentration was estimated
by absorbance at 260 nm in a Shimadzu spectrophotometer (Columbia, MD). Samples of
RNA were stored at -80 C.
RT-PCR
Reverse transcription (RT) was performed by adding 2 µg of total RNA to 2 µg of
Oligo dT primers and sterilized nuclease-free dd H2O in a final volume of 15 µl. The
samples were heated at 70 C for 5 minutes and then immediately cooled to 4 C for 2
minutes. Reverse transcription buffer containing dNTPs (final concentration of each was
10 mM), 25 units of RNase inhibitor, and 200 units of murine maloney leukemia virus
reverse transcriptase (Promega, Madison, WI) were added to each sample. The sample,
with a final volume of 40 µl, was incubated at 37 C for 1 hr followed by a 5 minutes
incubation at 95 C. For the PCR reaction, 2 µl of RT reaction mixture were added to 48
µl of solution containing 5 µl of Taq buffer, 1 µl Taq DNA polymerase (Display Systems
Biotech, Vista, CA), 1 µl dNTPs (final concentration of each was 10 mM), 1 µl each of
forward and reverse primers and 41 µl sterile nuclease-free dd H2O. The PCR reaction
started with one cycle consisting of 94 C for 5 minutes, an annealing step of 65 C for
myostatin and activin-B (55 C for follistatin and β-actin) for 1 minute and extension at 72
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C for 10 minutes. The first cycle was followed by 30 cycles (25 cycles for β-actin)
consisting of 30-sec intervals of 94 C, followed by 65 C for myostatin and activin-B, and
55 C for follistatin and β-actin, followed by 72 C. To establish a linear range of
amplification for each gene, several different cycle numbers of PCR (10, 15, 20, 25, 30
and 35 cycles) were run. As a control, PCR reaction mixture without c-DNA was run and
found no contamination in reaction mixture (data not shown).
PCR primers
All PCR primers were made by Gibco BRL Inc. (Grand Island, NY). Primers for
myostatin were designed on the basis of published sequences of chicken myostatin
(McPherron et al., 1997). The sequence of the forward primer was 5'
GACTATCATGCCACAACCGAGACGA 3', while the reverse primer was 5'
GTGTACCAGGTGAGTGTGCGGGTATT 3'. Forward and reverse primers predicted a
PCR product of 657 base pairs (bp), which corresponds to bases 327-984 of the sequence.
Primers for follistatin were designed on the basis of the published sequence of chicken
follistatin (Graham and Lumbsden, 1996). The sequence of the forward primer was 5'
CATCCCGTGCAAAGAAAC 3', while the reverse primer was
5'CTCGTAGGCTAATCCAATG 3'. These primers amplified a PCR product of 445 bp
as previously reported (Davis and Johnson, 1998), which corresponded to bases 260-705
of the sequence. Primers for activin-B were based on a published partial sequence
(Mitrani et al., 1990). The sequence of the forward primer was 5'
TACTGTGAAGGGAGCTGCCCG 3', while the reverse primer was 5'
GTACAGCATTGACATTGTGC 3'. These primers amplified a PCR product of 162 bp
as previously reported (Davis and Johnson, 1998), which corresponded to bases 13-175
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of the sequence. Primers for β-actin were used to amplify a 285 bp product as previously
published (Yamamura et al., 1991), as an internal standard to verify the level of
amplification. The sequence of the forward primer was 5'
TCATGAAGTGTGACGTTGACATCCGT 3', while the reverse primer was 5'
CCTAGAAGCATTTGCGGTGCACGATG 3'.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels
stained with ethidium bromide. Products were quantified by densitometric analysis of
stained gels. The identity of all PCR products was confirmed by sequence analysis.
Statistical analysis
Regression analysis was performed by the GLM procedure of SAS (1989).
Statements of significance were based on P < 0.05 unless otherwise noted.
RESULTS AND DISCUSSION
Myostatin mRNA
The regression equation for myostatin content was 0.992 - 0.24160 Day + 0.0266
Day2 – 0.000789 Day3 (P < 0.05, r2 = 0.413). Figure 1-A depicts the patterns of steadystate levels for myostatin mRNA during chicken embryonic development. Myostatin
gene expression was first seen during the blastoderm stage of the chick embryo
(unincubated embryo, E 0) and remained constant through E 1. Myostatin mRNA
dramatically declined on E 2 and remained lower through E 6. Levels then sharply
increased on E 7 and plateaued through E 16. Myostatin mRNA increased by E 17 and
remained high through E 19, then decreased prior to hatching. The highest and lowest
myostatin mRNA levels were seen in the 1- and 2-day-old chicken embryo, respectively.
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Although the main source of myostatin is skeletal muscle tissues (McPherron and
Lee, 1997), myostatin mRNA expression is certainly not limited to skeletal muscle
tissues. Myostatin mRNA was detected in adipose tissue and tubuloalveolar secretory
lobules of the lactating mammary gland (Ji et al., 1998). Our finding of strong expression
in the early chicken embryo (E 0 and E 1) is intriguing and suggests the possibility that
myostatin has an important role during early chicken embryonic development.
The ontogeny of myostatin mRNA (increase in thoracic/abdominal embryo
preparations at E 7 coupled with a high level of expression in skeletal muscle at E 17 and
the reduction prior to hatching) coincides roughly with the periods of primary and
secondary muscle fiber formation. Primary muscle fiber formation occurs by E 7 and
secondary muscle fiber formation occurs between E 7 and E 18 in chicken embryos
(Feredette and Landmesser, 1991). Because the myofibre number is mostly completed by
hatching, the reduction in myostatin mRNA abundance prior to hatching could be due to
the reduction in myogenic and mitogenic events. The developmental pattern of chicken
myostatin mRNA expression is similar to that reported for cattle (Kambadur et al., 1997)
and for pigs (Ji et al., 1998).
Follistatin mRNA
The regression equation for follistatin was 0.07026 + 0.05322 Day (P < 0.0001, r2
= 0.801). In figure 2-A, the steady-state levels of follistatin mRNA during chicken
embryonic development are shown. Follistatin gene expression was first seen during the
blastoderm stage of the chick embryo (unincubated embryo, stage 1, E 0). Overall
follistatin mRNA increased about 6 fold from E 1 to E 20 of embryonic development.
Follistatin mRNA levels decreased from E 0 to E 1 and remained low through E 5, then
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increased on E 6 and plateaued through E 9. Follistatin mRNA increased on E 10 (~ 2
fold) and were followed by an additional increase on E 13 and E 14. The same pattern as
seen between E 10 and E 14 was seen again between E 15 and E 19. Follistatin mRNA
then reached the highest levels prior to hatching. The lowest mRNA expression was seen
in the 3-day-old chick embryo.
Follistatin is ubiquitously expressed in rats (Tuuri et al., 1994) and chicken testes
and ovulatory follicles (Davis and Johnson, 1998). Early expression of the follistatin gene
(E 0) could be due to early embryonic developmental events. For instance, BMPs have
ventralizing properties, which result in the ectoderm displaying epidermal characteristics.
However, follistatin was able to prevent ventralization by the BMPs and allow the
ectoderm to follow a neural fate (Hemmati-Brivanlou et al., 1991).
Mice over-expressing follistatin had reduced fertility (Matzuk et al., 1996). Males
had smaller testes and females had smaller ovaries and thinner uteri, which suggests that
follistatin has a key role during sexual development. This could explain our findings of
an increase in follistatin mRNA levels between E 6 and E 9, which corresponds to the
time of sexual differentiation in chick embryos.
Activin-B mRNA
The regression equation for activin-B is 0.2904 + 0.0659 Day – 0.00347 Day2 (P
< 0.05, r2 = 0.359). In figure 2-B, the expression pattern of activin-B during chicken
embryonic development is shown. Activin-B gene expression was first seen during the
blastoderm stage of the chick embryo (unincubated embryo, stage 1, E 0). Although
activin-B mRNA from the whole embryo preparations fluctuated, it varied as the embryo
matured. The lowest mRNA level was seen on E 5, after which levels gradually increased

25

and reached the highest level at E 11. Overall activin-B gene expression from E 11 to E
20 appeared to decline (~ 3.5 fold).
Activins inhibit in vitro differentiation of myoblasts, while follistatin acts as a
local modulator to prevent this myogenic repression (Link and Nishi, 1997). Our results
were in partial agreement with these in vitro findings. For example, follistatin mRNA
increased from E 10 to E 20, while overall activin-B mRNA appeared to decrease
accordingly during this time period. On the other hand, follistatin mRNA increased from
E 10 to E 13 when the hypertrophic muscle growth is dominant. Our observation that
activin-B mRNA levels were not concomitantly low between these days suggests that the
actions of follistatin were not simply reciprocal to those of activins.
β-Actin mRNA
The regression equation for β- Actin was 279.067 + 32.256 Day – 2.649 Day2 +
0.06716 Day3 (P < 0.0001, r2 = 0.702). Figure 1-B demonstrates the expression patterns
of β-actin mRNA during chicken embryonic development. β-Actin was used as a housekeeping gene and appeared to be stable throughout chicken embryonic development.
Since we made no attempt to determine protein levels in the tissues used in this
study, nothing can be concluded on the translation of the myostatin, follistatin and
activin-B transcripts detected. However, based on the gene expression results, myostatin
could be a significant player in prenatal chicken skeletal muscle growth as well as growth
of whole embryos prior to when myogenic identity was established. Therefore, complete
understanding of the biochemistry and physiology of myostatin during early embryonic
development could be beneficial to human health and food animal agriculture. Follistatin
and activin-B were found to be clearly among the determinants of prenatal chicken
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muscle growth. Previous experiments demonstrated that the effects of activins and TGFβs on muscle development were distinct. Therefore, expression of TGF-βs in chicken
embryonic development could be of interest as a key regulator of these processes.
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Figure 1.

Steady-state levels of myostatin (A) and β-actin (B) mRNA in whole
embryo and pectoralis muscle during chick embryo development (n= 6 or
4 per day, respectively). The bands for myostatin on the photograph were
scanned by densitometer and the integration values (mean ± SD), after
normalization to β-actin, are expressed in arbitrary densitometric units at
each day.
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Figure 2.

Steady-state levels of follistatin (A) and activin-B (B) mRNA in whole
embryo and pectoralis muscle during chick embryo development (n= 6 or
4 per day, respectively). The bands for follistatin and activin-B on the
photograph were scanned by densitometer and the integration values
(mean ± SD), after normalization to β-actin, are expressed in arbitrary
densitometric units at each day.
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Chapter 2

THE TEMPORAL EXPRESSION OF GROWTH FACTOR GENES DURING
MYOGENESIS OF SATELLITE CELLS DERIVED FROM THE BICEPS
FEMORIS AND PECTORALIS MAJOR MUSCLES OF THE CHICKEN

(Published in: Kocamis et al., 2001. Journal of Cellular Physiology, 186: 146-152)
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INTRODUCTION

Satellite cells, which lie between the basal lamina and sarcolemma of the muscle
fiber (Mauro, 1961) are the myogenic stem cells of vertebrate skeletal muscle. They are
responsible for the processes of growth and repair in postnatal muscle. These cells are
considered mitotically quiescent until stimulated by growth factors to proliferate,
differentiate and fuse to existing muscle fibers (for review, see Dodson et al., 1996).
Among the most studied growth factors that have specific actions on the proliferation and
differentiation of myoblasts are transforming growth factor-betas (TGF-β), insulin-like
growth factors (IGF), and fibroblast growth factors (FGF). The IGFs and FGFs are
actively involved in control of proliferation and differentiation of several myogenic cell
lines. For example, IGFs stimulated the proliferation of chicken (Duclos et al., 1991) and
fish (Venkateswaran et al., 1995) satellite cells and also stimulated the proliferation and
differentiation of bovine-derived satellite cells (Greene and Allen, 1991). The mitogenic
effects of IGF-I and FGF on turkey embryonic myoblasts and satellite cells were
synergistic (McFarland et al., 1993), whereas the effects of these mitogens on chicken
satellite cells were only additive (Wilkie et al., 1995).
Myostatin, a recently identified member of TGF-β family, has been shown to
negatively regulate skeletal muscle growth (McPherron et al., 1997). Myostatin null
mutation mice showed a dramatic increase in skeletal muscle mass, primarily due to
increased number of muscle fibers (McPherron et al., 1997). Additionally, Carlson et al.
(1999) demonstrated that there was a positive correlation between abundance of
myostatin mRNA and several different muscles that predominantly express white myosin
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heavy chain proteins, particularly type IIb. Activins, which are also members of the
TGF-β family, have multiple biological effects in a wide variety of reproductive and nonreproductive tissues (for review see, Ying et al., 1997). Activins recently have been
shown to inhibit in vitro myoblast differentiation, while follistatin, an antagonist of
activins (for reviews see, Michel et al., 1993, Patel, 1998), acts as a local modulator to
prevent myogenic repression (Link and Nishi, 1997). Additionally, we have shown the
developmental pattern of myostatin, activin-B and follistatin gene expression during
chicken embryonic skeletal muscle development (Kocamis et al., 1999). Since satellite
cells are the major component of postnatal skeletal muscle growth, we wanted to
determine if satellite cells derived from two different muscle fiber-type sources express
these recently identified TGF-β family members myostatin, activin-B, and follistatin, and
whether the expression of these genes was regulated during myogenesis.
Satellite cells derived from the chicken pectoralis major (predominantly white
fibers, PM) and biceps femoris (predominantly red fibers, BF) muscles showed
differences in metabolic variables, and mitogenic responses to various concentrations of
chicken serum (McFarland et al., 1997). For instance, BF satellite cells were more
responsive to the mitogenic effects of chicken serum than PM satellite cells in the
chicken; PM satellite cells, however, differentiated faster than BF satellite cells when
induced to differentiate by administration of low-serum containing medium (McFarland
et al., 1997). For this reason, the objective of the present study was to evaluate whether
differences in gene expression for growth factors (TGF-β2, IGF-I, -II and basic, bFGF)
could explain the variation in properties of satellite cells isolated from different chicken
muscle types.
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MATERIALS AND METHODS

Cell isolation and culture
Satellite cells were isolated from the pectoralis major and biceps femoris muscles
of 5-week-old female Cornish Rock broiler chickens as previously described (McFarland
et al., 1997). Preliminary studies (data not shown) indicated that approximately 90% of
primary broiler chicken satellite cells stained positive for the muscle-specific marker,
desmin. Following proliferation for 6-7 days, these cultures were reduced to less than
30% desmine positive cells. Because of greatly diminished myogenicity of these primary
cultures, satellite cells from both the pectoralis major and biceps femoris were cloned to
produce pure myogenic cultures. Following cloning, only one clone from each muscle
source exhibited ≥ 50% fused cells when administered low serum-containing medium for
2 days. The remainder of clones fused to form cultures with a lowered percentage of
nuclei within myotubes. We, therefore, chose the biceps femoris clone BBF9 and
pectoralis major clone BPM8 for these studies. Cells were plated in 24-well plates at a
density of 7600 cells/well in DMEM + 10% chicken serum (CS) + 5% horse serum (HS)
and allowed to attach for 15 h in a CO2 incubator at 38.5C. Cells were then administered
McCoy’s 5A + 10% CS + 5% HS + 10 ng/ml basic fibroblast growth factor (bFGF) daily
for 3 days. Following this, cells were administered DMEM + 3% HS + 1 mg/mL gelatin
(fusion medium) daily for 3 days. Measurements of DNA (5 well replicates), creatine
kinase (5 well replicates) and RNA (3 replicates with 6 wells pooled/replicate) were
made at each time point.
DNA was quantified in wells by the use of a fluorescence plate reader as
previously described (McFarland et al., 1995). Differentiation was measured by
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determination of muscle specific creatine kinase levels using a plate reader. The
procedure was adapted from the method of Shainberg et al. (1971) as modified by Florini
(1989) using thio-NAD. Cell samples for RNA isolation were rinsed with PBS,
trypsinized from the substratum, quenched with soybean trypsin inhibitor and the cells
from each row (6 wells) were pooled for each of the 3 replicate samples. The
suspensions were centrifuged in microfuge tubes at 800 x g for 15 min at 4C, the
supernatants discarded, and the pellets frozen at –90C until assay.
RNA extraction
Total RNA was extracted from harvested cells at all of the time points mentioned
above using the Tri-Reagent (Sigma, St. Louis, MO) modification of the guanidine
isothiocyanate/phenol-chloroform method as described by Chomczynski and Sacci
(1987). The RNA concentration was estimated by absorbance at 260 nm in a Shimadzu
spectrophotometer (Model UV-1201, Columbia, MD). The integrity of the RNA was
assessed by UV visualization of ethidium-bromide stained intact 28S and 18S bands on a
mini-agarose gel. Samples of RNA were stored at -80 C.
RT-PCR
Reverse transcription (RT) was performed by adding 2 µg of total RNA to 2 µg of
oligo dT primers and sterilized nuclease-free dd H2O in a final volume of 15 µl. The
samples were heated at 70 C for 5 minutes and then immediately cooled to 4 C for 2
minutes. Reverse transcription buffer containing dNTPs (final concentration of each was
10 mM), 25 units of RNase inhibitor, and 200 units of murine maloney leukemia virus
reverse transcriptase (Promega, Madison, WI) were added to each sample. The sample,
with a final volume of 40 µl, was incubated at 37 C for 1 hr followed by a 5 min
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incubation at 95 C. For the PCR reaction, 2 µl of RT reaction mixture were added to 48
µl of solution containing 5 µl of Taq buffer, 1 µl Taq DNA polymerase (Display Systems
Biotech, Vista, CA), 1 µl dNTPs (final concentration of each was 10 mM), 1 µl each of
forward and reverse primers and 41 µl sterile nuclease-free dd H2O. The PCR reaction
started with one cycle consisting of 94 C for 5 min, an annealing step of 65 C (for bFGF
and activin-B) or 55 C (for IGF-I, myostatin, follistatin and β-actin) for 1 min and
extension at 72 C for 1 min. The first cycle was followed by 30 cycles (25 cycles for βactin) consisting of 30-sec intervals of 94 C, followed by 65 C for bFGF and activin-B, or
55 C for IGF-I, myostatin, follistatin and β-actin, followed by 72 C. To establish a linear
range of amplification for each gene, several different cycle numbers of PCR (10, 15, 20,
25, 30 and 35 cycles) were run. For IGF-II and TGF-β2, touchdown PCR was run. This
program consisted of a 5 min, 94C denaturation step, followed by 5 cycles in which the
initial annealing temperature of 72C for IGF-II and 65 for TGF-β2 was reduced by 1C
per cycle, then 30 cycles in which the annealing temperatures were 68C for IGF-II and
61C for TGF-β2. Denaturation, extention and annealing time were programmed as
described above. A water (no cDNA) PCR reaction was used as a control for each gene
and no contamination of reaction mixture components was found.
PCR primers
All PCR primers were obtained from Gibco BRL Inc. (Grand Island, NY).
Primers for myostatin were designed on the basis of published sequences of chicken
myostatin (McPherron and Lee, 1997). The sequence of the forward primer was 5'
GACTATCATGCCACAACCGAGACGA 3', while the reverse primer was 5'
GTGTACCAGGTGAGTGTGCGGGTATT 3'. Forward and reverse primers predicted a
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PCR product of 657 base pairs (bp), which corresponded to bases 327-984 of the
sequence. Primers for follistatin were designed on the basis of the published sequence of
chicken follistatin (Graham and Lumbsden, 1996). The sequence of the forward primer
was 5' CATCCCGTGCAAAGAAAC 3', while the reverse primer was
5'CTCGTAGGCTAATCCAATG 3'. These primers amplified a PCR product of 445 bp
as previously reported (Davis and Johnson, 1998), which corresponded to bases 260-705
of the sequence. Primers for activin-B were based on a published partial sequence
(Mitrani et al., 1990). The sequence of the forward primer was 5'
TACTGTGAAGGGAGCTGCCCG 3', while the reverse primer was 5'
GTACAGCATTGACATTGTGC 3'. These primers amplified a PCR product of 162 bp
as previously reported (Davis and Johnson, 1998), which corresponded to bases 13-175
of the sequence.
Primers for bFGF and TGF-β2 were designed on the basis of published sequences
of chicken bFGF and TGF-β2 (Borja et al., 1993; Burt and Paton, 1991, respectively).
Primers for bFGF amplified a PCR product of 270 bp which corresponded to bases 432701 of the sequence, while primers for TGF-β2 amplified a PCR product of 269 bp which
corresponded to bases 6452- 6722 of the sequence. The sequences of forward primers for
bFGF and TGF-β2 were 5’ GATCCGCACATCAAACTGC 3’, 5’
AGGAATGTGCAGGATAATT 3’, while the reverse primers were 5’
GATACGTTTCTGTCCAGGTCC 3’, 5’ ATTTTGGGTGTTTTGCCAA 3’, respectively.
Primers for IGF-I and IGF-II were designed on the basis of published sequences of
chicken IGF-I and IGF-II (Kajimoto and Rotwein, 1989; Darling and Brickell, 1996,
respectively). The sequences of forward primers for IGF-I and IGF-II were 5’
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GTATGTGGAGACAGAGGCTTC 3’, 5’ TGTGGAGGAGTGCTGCTTTC 3’, while the
reverse primers were 5’ TTTGGCATATCAGTGTGGCGC 3’, 5’
GGGAGGTGGCGGAGAGGTCA 3’, respectively. Forward and reverse primers
amplified a PCR product of 200 bp for IGF-I which corresponded to bases of 439-638,
while primers for IGF-II amplified a 101 bp PCR product which corresponded to bases of
44-145. Primers for β-actin were used to amplify a 285 bp product as previously
published (Yamamura et al., 1991), as an internal standard for normalizing the level of
amplification. The sequence of the forward primer was 5'
TCATGAAGTGTGACGTTGACATCCGT 3', while the reverse primer was 5'
CCTAGAAGCATTTGCGGTGCACGATG 3'.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels stained
with ethidium bromide. Products were analyzed by densitometry of stained gels, and data
should, therefore, be considered on a semi-quantitative basis. The identity of all PCR
products was confirmed by sequence analysis.
Statistical analysis
Analysis of variance was performed by the GLM procedure of SAS (SAS
Institute, 1989). Duncan’s New Multiple Range test was used to compare mean values of
PM and BF satellite cell DNA and creatine kinase ratios. Statements of significance were
based on P < 0.05 unless otherwise noted.

37

RESULTS

Proliferation rates and differentiation kinetics of PM and BF satellite cells are
shown in Figure 1 (A and B, respectively). Proliferation rates of BF satellite cell clone
used were greater than PM clone. However, PM satellite cells began differentiation
sooner than BF satellite cells.
β-Actin mRNA
Figure 2 depicts the patterns of β-Actin gene expression in both cell cultures. βActin was used as a housekeeping gene and was stable throughout the experiment in both
cultures.
TGF-β
β Family mRNA
Representative patterns of steady-state levels for myostatin and TGF-β2 mRNA
during PM and BF chicken satellite cell myogenesis are shown in figure 3. No myostatin
gene expression was detected in either satellite cell culture at 0 h and 24 h after plating.
The ontogeny of myostatin gene expression was nearly identical in both cell cultures.
However, myostatin mRNA level increased at 72 h after plating when fusion starts in BF
satellite cells (Fig. 3, P < 0.01), whereas there was no significant change in PM satellite
cells at this time. Myostatin mRNA, once it reached the highest value at 72 h, plateaued
through 144 h in both cell cultures (Fig. 3). TGF-β2 mRNA was first detected in 0 h
satellite cells derived from either PM or BF muscle and remained constant until 48 h
culture. Amounts then sharply increased (Fig. 3, P < 0.01) and remained constant until
the end of culture period in both PM and BF satellite cells. The patterns of activin-B and
follistatin gene expression in both cell cultures are shown in Figure 4. Activin-B and
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follistatin mRNAs were undetectable at 0 h in both satellite cell cultures. Activin-B
mRNA level in PM satellite cells was higher than in BP satellite cells at 72 h and 120 h
(Fig. 4, P < 0.01), whereas levels in BF satellite cells were higher than in PM satellite
cells at 96 h and 144 h (Fig. 4, P < 0.01). Amounts of follistatin mRNA in PM satellite
cells were higher than in BF satellite cells at 24, 96, and 120 h culture (Fig. 4, P < 0.01).
However, amounts in BF satellite cells were higher than in PM satellite cells at 144 h
after plating (P < 0.01).
IGF-I, -II and bFGF mRNA
Figure 5 shows the patterns of IGF-II and bFGF gene expression in both cell
cultures. Although, using the same primer sequences, Burt et al. (1992) demonstrated
IGF-I mRNA expression in different chicken tissues, no IGF-I gene expression was
detected in either cell culture at any time point in present study (data not shown). IGF-II
mRNA level plateaued in PM satellite cells by 48 h after plating (P < 0.05), and remained
elevated until 144 h of culture period. However, levels in BF satellite cells dramatically
declined at 96 h after plating (P < 0.01) and remained reduced until 144 h. No bFGF
mRNA was detected at 0 h satellite cells derived from either PM or BF muscle (Fig. 5).
bFGF gene expression in both satellite cell cultures increased at the 72 h culture period (P
< 0.05) and remained at this level in BF satellite cells through 144 h. Although bFGF
mRNA in PM satellite cells increased at 144 h with respect to 120 h of culture (P < 0.01),
amounts did not differ between PM and BF satellite cells at this time period (Fig. 5).
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DISCUSSION

The current study was conducted to evaluate differences in properties of satellite
cells isolated from different chicken muscle types. Clonal-derived satellite cell cultures
were used to eliminate the interference associated with nonmyogenic cell contamination
such as fibroblasts. It is possible that other clones within a given muscle may exhibit
variation in the gene expression of the various proteins we analyzed. However, studies to
examine this possibility will require improvements to increase the efficiency of cloning
of broiler chicken satellite cells. We determined that BF clone was more responsive to
mitogenic stimuli of serum than PM clone. However, PM satellite cells more rapidly
fused to form multinucleated myofibers than BF satellite cells. These findings were in
agreement with the results obtained by McFarland et al. (1997). On the other hand, the
observations seen with turkey BF and PM satellite cells, in which PM satellite cells were
more responsive to the mitogenic effects of serum (McFarland et al., 1995), were in
contrast to the results obtained from the present and previous (McFarland et al., 1997)
experiments. The reasons for these differences between species remain unclear.
TGF-βs inhibit proliferation and differentiation of satellite cells (Allen and
Boxhorn, 1987, 1989) as well as embryonic myoblasts in culture (Massague et al., 1986).
Lafyatis et al. (1991) demonstrated that TGF-β2 mRNA level increased in C2C12
myoblasts (cell line derived from satellite cells) when cells were allowed to differentiate
in low serum medium. In the present study, TGF-β2 mRNA level in both cultures,
however, reached the highest level before fusion started (72 h after plating) and remained
constant throughout the experiment. Also, the ontogeny of TGF-β2 gene expression in
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both cultures did not differ. Therefore, we suggest that TGF-β2 may not be involved in
the various response of PM and BF satellite cells to different serum concentrations.
Carlson et al. (1999) suggested that the higher concentrations of myostatin mRNA
in white muscles may function as an inhibitor of satellite cell proliferation. This
speculation is consistent with several previous experiments. First, myostatin knockout
mice showed muscle hyperplasia and hypertrophy (McPherron et al., 1997), both of
which do not occur if satellite cell proliferation is blocked in normal animals (Gulati,
1987). Second, muscles that predominantly have white fibers have low satellite cell
densities compared with muscles that predominantly have red fibers, which coincides
with the higher amount of myostatin expression in white muscles (Carlson et al., 1999;
Wehling et al., 2000). Third, animals subjected to hind limb unloading which causes
suppression of satellite cell proliferation (Darr and Schultz, 1989) demonstrated high
level of myostatin expression (Carlson et al., 1999). However, our results did not support
the speculation suggested by Carlson et al. (1999), because myostatin gene expression
was nearly identical in both PM and BF satellite cell cultures. The conclusions drawn by
Carlson et al. (1999) were based on whole muscle analyses, which included not only
satellite cells but also a major contribution of mRNA originating from myonuclei.
Myostatin levels within the muscle proper may differ from the levels found in pure
satellite cell population. On the other hand, myostatin proteins with different molecular
masses were found in the plantaris (predominantly red fibers) and soleus (predominantly
white fibers) muscles of rats (Wehling et al., 2000) suggesting that alternative
posttranslational modifications of myostatin occur in different muscle fibers. Since
myostatin gene expression in PM and BF satellite cells used in the present study was not
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different, it would be of interest to know whether the same myostatin protein
modifications take place in satellite cells derived from PM and BF muscles and whether
they are similar to those found in mature muscle.
Activins are covalently-linked dimers of two distinct β subunits, thus existing in
three different forms, activin-A, AB and B (Ying, 1987), whereas follistatin is a
monomeric glycosylated protein present in several isoforms (for reviews see, Michel et
al., 1993; Patel, 1998). Most, if not all, of the biological actions of activins are
neutralized by its binding to follistatin (reviewed in Michel et al., 1993). Follistatin is
also believed to interact with, and possibly regulate activities of, members of the TGF-β
superfamily. Activin and follistatin mRNAs (Kocamis et al., 1999) and protein (Link and
Nishi, 1997) expression have been shown in vivo during chicken pectoral muscle
development and in cultures derived from this muscle group. Activins inhibited pectoral
muscle cell differentiation in culture, while follistatin stimulated this processes (Link and
Nishi, 1997). Also, it was shown that the effects of activin on muscle cell differentiation
were different than those of TGF-βs in vitro (Link and Nishi, 1997). Consistent with the
latter findings, the pattern of activin-B gene expression from both satellite cultures was
different from that of TGF-β2 in the current study. Furthermore, overall activin-B and
follistatin mRNA expression patterns (i.e. both increased at 72 h after plating when
fusion started) found in PM satellite cells may contribute to the inhibitory functions of
follistatin on activins. For these same genes, the parallel expression patterns, however,
did not exist in BF satellite cells in culture. Therefore, it is suggested that follistatin may
predominantly interact with either other activin isoforms or other TGF-β superfamily
members, such as bone morphogenic proteins.
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Basic fibroblast growth factor (bFGF) was chosen to represent the FGF family
gene expression, because it was shown to be a more potent mitogen than acidic FGF for
chicken satellite cells (Wilkie et al., 1995). Moore et al. (1991) observed that FGF
mRNAs and their receptor were down-regulated during myoblast differentiation in
culture, and suggested that FGFs acted in an autocrine fashion to control myogenesis.
This hypothesis was supported by a study that demonstrated that myoblasts transfected
with an FGF antisense expression vector differentiated faster than control transfected
cells (Fox et al., 1994). On the contrary, amount of bFGF mRNA in the present study
were increased during differentiation and remained high in both satellite cell cultures.
Although FGF receptor numbers and affinities were similar in turkey PM and BF satellite
cells (McFarland et al., 1997), this may not be the case in chicken due to the different
response of these satellite cells to various concentrations of serum.
It has been shown that exogenous IGFs (IGF-I and –II) stimulated the
proliferation of chicken (Duclos et al., 1991) and turkey (McFarland et al., 1993) satellite
cells in vitro, whereas they did not stimulate the differentiation of turkey satellite cells
(McFarland et al., 1993). Based on the report by Florini et al. (1991) that high-IGFproducing rodent myoblast cell lines appeared relatively insensitive to exogenous IGFs, it
was speculated that the high amount of endogenous IGFs produced by turkey satellite
cells may be sufficient to allow maximal cell differentiation. However, this speculation
was disproved by Ernst et al. (1996) who showed that turkey satellite cells did not
express the IGF-I gene and that IGF-II production by these cells was highest in
proliferating cells and significantly decreased during differentiation. Our results that
IGF-I gene expression was not detected in either chicken PM or BF satellite cell cultures
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were consistent with results obtained by Ernst et al. (1996). On the other hand, IGF-II
gene expression in the current study was highest at 72 h after plating when fusion started
and remained high throughout the culture period in PM satellite cells. Given the fact that
IGF-I and IGF-II only act through the type-I receptor on chicken (Duclos et al., 1991)
and turkey (Sun et al., 1992) satellite cells, IGF-II may have autocrine/paracrine
functions in muscle development, whereas IGF-I may predominantly act in an endocrine
fashion.
Because of the lack of specific antibodies to the chicken gene products, no
attempt was made to determine amount of protein in cell cultures used in the present
study. Therefore no conclusions can be drawn as to the translational efficiency or
modifications of the growth factor transcripts studied. Additionally, the genes examined
in the present study were not conducive for the design of a multiplex PCR assay which
would have yielded quantitative data. Our results should, thus, be considered on a semiquantitative basis in light of the observed expression patterns for the various growth
factor genes. It is likely that changes in the proteins for the individual genes will roughly
parallel their mRNA patterns. As indicated earlier, posttranslational modifications to the
proteins may have a significant effect on their activities and ultimately on the cellular
response.
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Figure 1.

Comparison of the proliferation rates (A) and differentiation
kinetics (B) of PM and BF satellite cells. Cultures were evaluated
as described in materials and methods. Asterisks indicate when
proliferation and differentiation levels were significantly different
(P < 0.05).
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Representative steady-state levels of β-actin mRNA in in vitro PM and BF
satellite cell myogenesis (n= 3, per time point). The bands for β-actin
mRNA were analyzed by densitometry and the integration values (mean ±
SD) were expressed in arbitrary densitometric units at each time point.
Means with the same superscripts were not significantly different.
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Chapter 3

MYOSTATIN, FOLLISTATIN, ACTIVIN-B AND TGF-β
β2 GENE EXPRESSION
PATTERNS IN RESPONSE TO IN OVO ADMINISTRATION OF rhIGF-I
DURING CHICKEN EMBRYONIC DEVELOPMENT
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INTRODUCTION

Insulin-like growth factors (IGF) and transforming growth factor-betas (TGF-β)
are the most studied growth factors that have specific actions on the proliferation and
differentiation of myoblasts. Exogenous IGFs stimulated both proliferation and
differentiation of several myogenic cell lines (Florini et al., 1991), while TGF-βs
inhibited myogenesis in those cells albeit with various magnitude (Florini et al., 1986,
Massague et al., 1986). Additionally, in vitro studies indicated that IGF-I negatively
controlled TGF-β expression during early myogenesis (Bosche et al., 1995).
Myostatin, a recently identified member of the TGF-β family, has been proposed
as a negative regulator of skeletal muscle growth. The ontogeny of myostatin gene
expression during chicken embryonic development suggested that myostatin could be a
major determinant in prenatal skeletal muscle growth as well as growth of whole
embryos (Kocamis et al., 1999). We have previously demonstrated that in ovo
administration of recombinant human insulin-like growth factor-I (rhIGF-I, 100 ng/per
egg) on embryonic day 3 (E3) significantly increased the postnatal muscle growth of 42day-old chickens (Kocamis et al., 1998, 2000). Therefore, the objective for this study
was to evaluate the impact of in ovo administration of rhIGF-I on myostatin, activin-B
(member of the TGF-β family), follistatin (an antagonist of activins), and TGF-β2 gene
expression during chicken embryonic development with emphasis on skeletal muscle
development.
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MATERIALS AND METHODS
Injection Procedure

Fertilized eggs (Ross x Ross) were obtained from Wampler-Longacre
(Moorefield, WV). The injection procedure was described previously (Kocamis et al.,
1998). Briefly, 100 ng/100 µL per egg of rh IGF-I (R & D Systems, Minneapolis, MN) in
10 mM acetic acid, 0.1 % BSA was administered with a 22-gauge needle through the
blunt end of the egg on embryonic day 3. Prior to injection, the blunt end of the egg was
sterilized with 70% ethanol. A dental drill bit was used to create a single hole, without
penetrating the chorio-allantoic membrane. The hole was sealed with an adhesive sticker.
Because no difference was previously found between vehicle (10 mM acetic acid, 0.1 %
BSA) injected and uninjected groups (Kocamis et al., 1998, 2000) in terms of postnatal
skeletal muscle growth, uninjected eggs were used as control group in the present study.
Eggs were set in a Buckeye incubator/hatcher (temperature 37 ± .5 C, humidity 86 to
87%).
Tissue collection
Embryos and tissues were harvested in compliance with an approved West
Virginia University Animal Care and Use Committee Protocol. Tissue collection was
performed as previously described (Kocamis et al., 1999). Briefly, all the embryos were
isolated and washed free of yolk, albumen and extra-embryonic membranes by sterile
nuclease-free water and were staged according to Hamburger and Hamilton (1951).
Whole embryos were collected on each embryonic days (E) 0 to 6 (equivalent to stage 1
to stage 29, n= 6 per day). Thoracic/abdominal halves of embryos consisting of the
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lumbo-sacral level to the neck without head were collected on each of E 7 and E 8 (stage
31 and stage 34, respectively, n= 6 per day). Pectoralis muscle was collected on each of
E 9 to E 20 (n= 4 per day). All the tissue collections were performed at consistent times
for each sampling day throughout the experimental period, starting day 9, stage 35, and
every 24 h until day 20, stage 45.
RNA extraction and RT-PCR
Total RNA was extracted from all of the tissues mentioned above using the TriReagent (Sigma, St. Louis, MO) modification of the guanidine isothiocyanate/phenolchloroform method (Chomczynski and Sacci, 1987). The RNA concentration was
estimated by absorbance at 260 nm in a Shimadzu spectrophotometer (Columbia, MD).
Samples of RNA were stored at -80 C.
Reverse transcription (RT) was performed as described in chapter 1. The PCR
reaction started with one cycle consisting of 94 C for 5 minutes, an annealing step of 65
C for myostatin, and activin B, or 55 C for follistatin and β-actin for 1 minute and
extension at 72 C for 1 minute. The first cycle was followed by 30 cycles (25 cycles for
β-actin) consisting of 30-sec intervals of 94 C, followed by 65 C for myostatin and
activin-B or 55 C for follistatin and β-actin, followed by 72 C. For TGF-β2, touchdown
PCR was run. This program consisted of a 5-minute, 94 C denaturation step, followed by
5 cycles in which the initial annealing temperature of 65 was reduced by 1C per cycle,
then 30 cycles in which the annealing temperature was 61C. Denaturation, extension and
annealing time were programmed as described above. To establish a linear range of
amplification for each gene, several different cycle numbers of PCR (10, 15, 20, 25 and

53

30 cycles) were run. As a control, a PCR reaction without c-DNA was run, and no
contamination was found in reaction mixture (data not shown).
PCR primers
All PCR primers were synthesized by Gibco BRL Inc. (Grand Island, NY).
Primer designs, sequences and expected product sizes for myostatin, activin-B, follistatin
and β-actin were described in the chapter 1. Primers for TGF-β2 amplified a PCR
product of 269 bp which corresponded to bases 6452- 6722 of the sequence. The
sequence of the forward primer for TGF-β2 was 5’ GATCCGCACATCAAACTGC 3’,
while the reverse primer was 5’ ATTTTGGGTGTTTTGCCAA 3’.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels
stained with ethidium bromide. Products were analyzed by densitometry of stained gels,
and data should, therefore, be considered to be semi-quantitative. The identity of all
PCR products was confirmed by sequence analysis. Mean gene expression values for
each day were derived from a minimum of four individual sample collections and a
minimum of three independent cDNA and RT-PCR amplifications per sample.
RESULTS
Myostatin gene expression was first seen in 4-day-old chicken embryos and then
gradually increased through embryonic day 8 (E 8) in both control and in ovo rhIGF-I
injected groups (Fig. 1). Myostatin mRNA levels from control pectoralis muscle sharply
increased at E 9 (~ 3 fold) and remained high through E 12. Values then decreased and
remained low until E 16. Myostatin expression subsequently increased (~ 3 fold) and
remained high until hatching. Myostatin mRNA from pectoralis muscles of rhIGF-I
injected embryos increased on E 10 (~ 2.5 fold) and remained high through E 13,
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whereas mRNA from control pectoralis muscles increased at E 9 and remained high
until E 12.
Follistatin gene expression was first detected on E 0(Fig. 2). Follistatin mRNA
levels from control embryos gradually increased from E 3 to E 8, whereas levels from
rhIGF-I injected group remained relatively constant between these days, with the sudden
increase at E 5 (~ 2 fold). Follistatin mRNA levels from pectoralis muscles of rhIGF-I
injected group were increased at E 12 (~ 2.5 fold) and reached the highest level at E 13.
Levels then gradually declined through E 20. However, follistatin mRNA from control
pectoralis muscle remained relatively constant between E 9 and E 15. Levels then sharply
decreased at E 16 (~ 3 fold) and followed by sudden increase at E 17 (~ 3.5 fold) and
reached the highest level at E 19.
Activin-B gene expression was first seen at E 0 and fluctuated through E 8 in
control embryos (Fig. 3). However, levels from rhIGF-I injected group from E 3 to E 8
remained relatively constant. In both control and rhIGF-I injected group, activin-B
mRNA levels sharply increased at E 8 (~ 2.5 fold) and remained high through E 13.
Levels from control group then decreased (~ 2 fold) and remained relatively constant
until E 20 whose expression was the highest in this group. Activin mRNA levels from
rhIGF-I injected pectoralis muscle fluctuated from E 14 to E 20, with slight decrease.
TGF-β2 gene expression was first found at E 2 and gradually increased until E 7
in both control and in ovo rhIGF-I injected chicken embryos (Fig. 4). TGF-β2 mRNA
levels from control pectoralis muscle remained relatively constant from E 9 to E 12, then
dramatically increased at E 14 (~ 3 fold) and remained high until E 17. TGF-β2 gene
expression sharply declined (~ 2.5 fold) and remained low until hatching. TGF-β2
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mRNA from pectoralis muscles of in ovo rhIGF-I treated embryos dramatically
increased at E 13 (~ 2.5 fold), in contrast to E 14 from control pectoralis muscle, and
gradually declined through E 16. Additionally, TGF-β2 gene expression in the in ovo
rhIGF-I injected group, unlike the control groups, showed a sudden increase at E 18
prior to hatching.
Figure 5 depicts the patterns of β-Actin gene expression in both control and in ovo
rhIGF-I injected chicken embryos. β-Actin was used as a housekeeping gene and was
stable throughout the experiment in both groups.
DISCUSSION
Strong myostatin mRNA expression in chicken (Cobb X Cobb) was previously
seen during the blastoderm stage of embryos and remained high through embryonic day 2
(Kocamis et al., 1999), whereas the same expression pattern was not observed in Ross X
Ross chicken embryos of the present study. Because the Ross X Ross strain is considered
a fast growing chicken lines, the different myostatin expression pattern between these
two strains could be due to the different growth rate of these birds. Therefore, early
myostatin expression may not only determine muscle growth but also play a pivotal role
in early embryonic growth, which ultimately gives rise to either faster or slower growing
chicken lines. Nevertheless, this assumption needs to be further explored. Skeletal
muscle tissue is widely believed to be the main source of myostatin (McPherron et al.,
1997). Embryonic chicken myoblasts begin to form in somites at approximately E 2.5
(for review, Stockdale et al., 2000). It is, therefore, possible to postulate that early
myostatin expression (E 4) in the present study originated from those presumptive
myoblasts. However, this assumption does not preclude the possibility of myostatin
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expression generated from other early chicken embryonic tissues, because myostatin
mRNA was detected in adipose tissues and tubuloalveolar glands (Ji et al., 1998).
Therefore, further studies using in situ hybridization should be conducted to verify the
exact origin of myostatin gene expression in early chicken embryonic development.
Overall follistatin gene expression profile from control group supported our
previous findings which demonstrated that follistatin mRNA level increased in a linear
fashion from E 1 to E 20 (Kocamis et al., 1999). A single in ovo rhIGF-I injection
seemed to shift the overall follistatin gene expression in chicken embryos and
subsequently in pectoralis muscle while having less pronounced effect on activin-B
expression. Activin-B gene expression pattern from control embryos was similar to our
previous findings which showed that overall activin-B mRNA expression followed a
quadratic fashion throughout embryonic development (Kocamis et al., 1999). Given the
fact that most, if not all, of the biological actions of activins are neutralized by its binding
to follistatin (Michel et al., 1993), activin-B and follistatin gene expression from control
groups should follow the parallel ontogeny during embryonic development, irrespective
of tissue or whole embryo. However, this was not observed in the present study, perhaps
due to broad inhibitory effect of follistatin with other TGF-β family members such as
bone morphogenic proteins.
It was shown that exogenous IGF-I stimulated differentiation of L6A1 myoblasts
through a process that involves myf-5 and an increase in the level of myogenin
expression (Florini et al., 1991). Also, exogenous IGF-I suppressed the IGF-II
expression in those cell lines (Magri et al., 1994). For this reason, the influence of in ovo
rhIGF-I on myogenic regulatory genes (myoD, myf-5, MRF-4 and myogenin) and IGF-
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II gene expression during chicken embryonic muscle development is under investigation
in our laboratory. In the current study TGF-β2, a well known representative member of
the TGF-β family, was chosen to determine whether the myostatin response to the in ovo
administration of rhIGF-I was distinct from that of the other TGF-β family members.
As shown in figure 2, TGF-β2 gene expression, unlike myostatin, demonstrated late
response (E 13 versus E 9) to the rhIGF-I. Bosche et al. (1995) demonstrated that each
TGF-β isoform investigated in L6A1 myoblast cell culture responded differently to the
addition of IGF-I. For instance, TGF-β2 was less responsive than TGF-β1 and TGF-β3.
These findings could, to some extent, explain the varying response of myostatin,
follistatin, activin-B, and TGF-β2 gene expression in the rhIGF-I treated group.
Even though growing pigs postnatally treated with porcine growth hormone (GH)
showed ~ 35% increased muscle mass, myostatin mRNA abundance in skeletal muscle
tissues of these animals was not affected (Ji et al., 1998). This hypertrophic growth was
due predominantly to satellite cell proliferation and the incorporation of these nuclei into
existing myofibers. Given the fact that GH exerts its mitogenic functions mainly
through liver IGF-I production (for review, Florini et al., 1996), IGF-I stimulated
satellite cell proliferation may not be due directly to an alteration of myostatin gene
expression. Additionally, IGF-I gene expression, unlike myostatin, was not detected in
satellite cells derived from either pectoralis major or biceps femoris muscles of chicken
(Kocamis et al., 2001). Therefore, the physiological role of myostatin in muscle may
mainly be associated with the prenatal period of muscle growth, which coincides with
our findings of altered developmental myostatin expression pattern in response to in ovo
rhIGF-I during embryonic development.
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Although overall myostatin expression patterns in both control and rhIGF-I
injected groups seem to be similar during embryonic pectoralis muscle development, in
ovo administration of rhIGF-I on E 3 appeared to delay myostatin expression
approximately one day compared to control embryos. A delay of myostatin expression
would allow myoblasts additional time in the replicative cell cycle which would
ultimately lead to increased muscle fiber formation. Thus, delayed expression of
myostatin may be responsible for the muscle hyperplasia associated with postnatal
chicken skeletal muscle increase due to in ovo rhIGF-I administration (Kocamis et al.,
1998, 2000).
There is a delicate balance between autocrine and paracrine production of growth
factors as well as endocrine production of hormones to ensure that a consistent number
of muscle fibers are formed. Increased muscle mass in response to a single
administration of in ovo rhIGF-I during early chicken embryonic development (Kocamis
et al., 1998, 2000) might be due to a perturbation of this homeostatic balance of factors
produced locally in the muscle. However, considering the complexity of the IGF
system, such as secretion of binding proteins and presence of two surface receptors, it is
difficult to pin-point the exact mechanism of a single in ovo rhIGF-I injection that
altered developmental expression patterns of myostatin, follistatin, activin-B and TGFβ2 genes during chicken embryonic development. In conclusion, our results
demonstrate that in ovo administration of rhIGF-I on E 3 alters developmental
expression patterns of myostatin, follistatin, and activin-B and TGF-β2 genes. A
complete understanding of the interaction between IGF-I and the TGF-β family genes
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during embryonic development could be beneficial to human health and food animal
agriculture.
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Figure 1.

Representative steady-state levels of control and IGF-I treated group
myostatin mRNAs in whole embryo and pectoralis muscle during chicken
embryonic development (n= 6 or 4 per day, respectively). The bands for
myostatin mRNA were analyzed by densitometry and the integration
values (mean ± SD), after normalization to β-actin, were expressed in
arbitrary densitometric units at each sampling day.
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Figure 2

Representative steady-state levels of control and IGF-I treated group
follistatin mRNAs in whole embryo and pectoralis muscle during chicken
embryonic development (n= 6 or 4 per day, respectively). The bands for
follistatin mRNA were analyzed by densitometry and the integration
values (mean ± SD), after normalization to β-actin, were expressed in
arbitrary densitometric units at each sampling day.
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Figure 3

Representative steady-state levels of control and IGF-I treated group
activin-B mRNAs in whole embryo and pectoralis muscle during chicken
embryonic development (n= 6 or 4 per day, respectively). The bands for
activin-B mRNA were analyzed by densitometry and the integration
values (mean ± SD), after normalization to β-actin, were expressed in
arbitrary densitometric units at each sampling day.
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Figure 4

Representative steady-state levels of control and IGF-I treated group TGFβ2 mRNAs in whole embryo and pectoralis muscle during chicken
embryonic development (n= 6 or 4 per day, respectively). The bands for
TGF-β2 mRNA were analyzed by densitometry and the integration values
(mean ± SD), after normalization to β-actin, were expressed in arbitrary
densitometric units at each sampling day.
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Figure 5

Representative steady-state levels of control and IGF-I treated group βactin mRNA in whole embryo and pectoralis muscle during chicken
embryonic development (n= 6 or 4 per day, respectively). The bands for βactin mRNA were analyzed by densitometry and the integration values
(mean ± SD) were expressed in arbitrary densitometric units at each
sampling day.
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Chapter 4

IGF-I, IGF-II AND IGF RECEPTOR-I TRANSCRIPT AND PROTEIN
EXPRESSION IN MYOSTATIN KNOCKOUT MICE TISSUES
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INTRODUCTION
Insulin-like growth factors (IGF-I and -II) are produced by several different
tissues and are essential for both embryonic and postnatal development (Coolican et al.,
1997, LeRoith, 1997). Severe disruption of tissue development, particularly in skeletal
muscles, was observed in IGF-I or IGF-II knockout mice. For instance, IGF-I knockout
mice were significantly smaller than their control littermates and had severe muscular
dystrophy (Powell-Braxton et al., 1993), whereas transgenic mice overexpressing IGF-I
showed enhanced body growth with an increase in muscle mass (Mathews et al., 1988).
Additionally, IGF-II expression has been positively associated with skeletal muscle
development in double-muscled cattle (Keller et al., 1999) and in pig breeds with
exceptional muscle mass (Nezer et al., 1999). In vitro, both IGFs inhibited apoptosis
(Wingertzahn et al., 1998) and promoted proliferation and differentiation of skeletal
muscle cells (Bark et al., 1998). As evidenced by these in vivo and in vitro findings,
IGFs are undoubtedly important components of skeletal muscle development.
When the myostatin gene (also known as growth differentiation factor/8), a
recently identified member of the TGF-β family, was disrupted by homologous
recombination in mice, skeletal muscle mass significantly increased, up to the three times
normal size (McPherron et al., 1997). Increased muscle mass in these mice was due
predominantly to hyperplasia but also involved hypertrophy. Additionally, myostatin
mutation resulting in functional loss of the protein has been linked to double-muscled
cattle breeds (Grobert et al., 1997, Kambadur et al., 1997). Therefore, myostatin has been
proposed to be a negative regulator of skeletal muscle growth. We postulated that the
ratio of mRNA and protein levels between IGFs, positive regulators of muscle growth,
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and myostatin, a negative regulator, may serve as indicators of skeletal muscle mass.
Also, based on the gene knockout observations, IGFs, in addition to being a pivotal
regulator of muscle growth, appear to be involved in controlling overall growth, whereas
myostatin seems to be acting only on muscle growth. Thus, to demonstrate whether a
correlation exists between IGFs and myostatin, IGF-I, -II and IGF receptor-I mRNA
(IGF-R1) and protein levels were determined in a wide variety of myostatin knockout
mice tissues.

MATERIALS and METHODS
Animals
Nine months old male myostatin knockout (n= 3) and control mice (n= 3,
SVJ/129) were generously provided by Metamorphix Inc., (Baltimore, MD). Euthanasia
of mice and subsequent tissue collections were performed in compliance with an
approved West Virginia University Animal Care and Use Committee Protocol.
RNA extraction and RT-PCR
Total RNA was extracted separately from myostatin knockout and control mouse
brain, heart, liver, kidney, and skeletal muscle tissues (soleus, gastrocnemius, and
pectoralis) using the Tri-Reagent (Sigma, St. Louis, MO) modification of the guanidine
isothiocyanate/phenol-chloroform method (Chomczynski and Sacci, 1987). The RNA
concentration was estimated by absorbance at 260 nm using a Shimadzu
spectrophotometer (Columbia, MD). Samples of RNA were stored at -80 C.
Reverse transcription (RT) was performed as described in Chapter 1 and 2. The
PCR reaction started with one cycle consisting of 94 C for 5 minutes, an annealing step
of 65 C for IGF-I or 55 C for IGF-II and β-actin for 1 minute and extension at 72 C for 1
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minute. The first cycle was followed by 30 cycles (25 cycles for β-actin) consisting of
45-sec intervals of 94 C, followed by 65 C for IGF-I or 55 C for IGF-II and β-actin,
followed by 72 C. For IGF-RI, touchdown PCR was run. This program consisted of a 5minute, 94 C denaturation step, followed by 5 cycles in which the initial annealing
temperature of 72 was reduced by 1C per cycle, then 30 cycles in which the annealing
temperature was 68C. Denaturation, extension and annealing time were programmed as
described above. To establish a linear range of amplification for each gene, several
different cycle numbers of PCR (10, 15, 20, 25 and 30 cycles) were run. As a control, a
PCR reaction without c-DNA was run, and no contamination was found in the reaction
mixtures (data not shown).
PCR primers
All PCR primers were synthesized by Gibco BRL Inc. (Grand Island, NY).
Primers for IGF-I were designed on the basis of published sequences of chicken IGF-I
(Bell et al., 1986). The sequence of the forward primer was
5'GCTGAGCTGGTGGATGCTCTTCAGTTC3', while the reverse primer was 5'
CTTCTGAGTCTTGGGCATGTCAGTGTG 3'. Forward and reverse primers predicted a
PCR product of 215 base pairs (bp), which corresponds to bases (160-265) of the
sequence. Primers for IGF-II were designed on the basis of published sequences of
chicken IGF-II (Rotwein and Hall, 1990). Primers for IGF-II amplified a PCR product of
356 bp which corresponded to bases (1041-1397) of the sequence. The sequence of the
forward primer for IGF-II was 5’ GAGCTTGTTGACACGCTTCAGTTTGTC 3’, while
the reverse primer was 5’ ACGTTTGGCCTCTCTGAACTCTTTGAG 3’. Primers for
IGF-RI were designed on the based of published sequence of mouse IGF-I (Wada et al.,
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1993). The sequence of the forward primer was 5’ GACATCCGCAACGACTATCAG3’,
while the reverse primer was 5’ GTAGTTATTGGACACCGCATC 3’. Primers for IGFRI amplified a PCR product of 395 bp which corresponded to bases (114-509) of the
sequence. Forward and reverse primers for β-actin were predicted to amplify a 285 bp
product as previously published (Yamamura et al., 1991), as an internal standard to verify
the level of amplification. The sequence of the forward primer was 5'
TCATGAAGTGTGACGTTGACATCCGT 3', while the reverse primer was 5'
CCTAGAAGCATTTGCGGTGCACGATG 3'.
The amplified PCR products for each gene were visualized on 1.5 % agarose gels
stained with ethidium bromide. Products were analyzed by densitometry of stained gels,
and data should, therefore, be considered to be semi-quantitative. The identity of all PCR
products was confirmed by sequence analysis.
Immunohistochemistry
Kidney and soleus muscles from adult myostatin knockout and control mice were
immersion fixed in Prefer fixative (Anatech, Battle Creek, MI). Sections were processed
overnight and embedded in paraffin. Unstained sections were cut at 5 microns and
incubated at 60`C for 20 minutes. Sections were then deparaffinzed in 3 baths of xylene
(6 minutes each), a bath of 100% alcohol (3 minutes), a bath of 95% alcohol (3 minutes),
a bath of 80% alcohol (3 minutes) and a final bath of distilled water for 5 minutes. The
sections were then placed in a coplin jar with 0.01M EDTA (pH = 8, Fisher Scientific,
Pittsburgh, PA) for antigen retrieval. Coplin jar was placed in microwave on high for 1
minute, 45 seconds to bring temperature up to boiling. A defrost cycle was set for 6
minutes that kept the solution just below boiling. After 6 minutes, the coplin jar was
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removed from the microwave and allowed to sit for 20 minutes. The slides were then
rinsed and incubated in distilled water for 5 minutes. All procedures for
immunochemistry were done in a Humidity Chamber (Shandon Lipshaw, Pittsburgh,
PA). Slides were incubated in3% hydrogen peroxide for 10 minutes at room temperature.
After rinsing with distilled water, slides were incubated in Tissue Conditioner (Biomeda,
Foster City, CA) for 10 minutes at 37` C (no humidity chamber). Slides were rinsed with
distilled water and placed in TBS (Dako, Carpinteria, CA) for 5 minutes. After diluting
with antibody diluent (1/100, Dako, Carpinteria, CA), IGF-II goat anti human antibody
(Sigma, St. Louis, MO) was applied as a dropp on section for 1 hour at room temperature.
Slides were then rinsed with distilled water and incubated in TBS for 5 minutes at room
temperture. Vectastain biotinylated secondary antibody (anti goat IgG) was applied as
outlined by manufacturer (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) for
30 minutes at RT. Slides were then rinsed with distilled water and incubated in TBS for 5
minutes at room temperature. Vectastain ABC (avidin-biotinylated enzyme complex)
reagent was applied for 30 minutes at RT. Slides were rinsed with distilled water and
incubated in TBS for 5 minutes at room temperature. Aqueous Hematoxylin (Biomeda,
Foster City, CA) was applied as a drop on over section for 2 minutes to counterstain.
Then slides were rinsed in tap water and coversliped with Crystal Mount (Biomeda,
Foster City, CA). After crystal mount was dried, they were post mounted with Permount
(Fisher Scientific, Pittsburgh, PA) and a glass coverslip. Whole section digital images
were captured using a Sprint Scan slide scanner. Digital photomicrographs were captured
using a Quantix digital camera. For digital capture, images from control and knockout
mice were captured in the same session using identical settings. As described in appendix
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D, western blotting was used to validate the quality of the primary antibody. Rabbit Super
Sensitive Control Serum (Biogenex, San Ramon, CA) in place of primary antibody was
used as a negative control on one section for each run.
Statistical Analysis
PDIFF of LS means was used to compare means (GLM procedure of SAS, SAS
Institute, 1989).
RESULTS
β-Actin, IGF-I, IGF-II and IGF-R1 mRNA Expression
β-Actin mRNA expression was not different for the same tissues between control
and myostatin knockout mice (Fig. 1). IGF-I gene expression for brain, heart, liver,
kidney and pestoralis muscles were similar between control and knockout mice, while no
IGF-I mRNA was detected in either control or knockout mice soleus muscles (Fig. 2).
IGF-II mRNA levels were significantly higher in myostatin knockout mice kidney and
soleus muscles than that of control mice (P < 0.01, Fig. 3). No IGF-II gene expression
was observed in liver and kidney of control mice, but only in liver of myostatin knockout
mice (Fig. 3). IGF-Receptor-1 mRNA levels from control mice heart (P < 0.05) and
kidney (P < 0.01) were significantly higher than that of myostatin knockout mice, while
levels were lower in control mice pectoralis muscle than that of knockout mice (P < 0.01,
Fig. 4). IGF-R1 gene expression was similar in brain, liver, soleus and gastrocnemius
muscles of both control and myostatin knockout mice.
IGF-II Immunohistochemistry
An IGF-II immunohistchemistry negative control is shown in figure 5. IGF-II was
principally localized to small cells located adjacent to soleus muscle myofibers (Fig. 6).
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The strongly IGF-II positive cells were common in myostatin knockout mice and were
seen in a few foci in control mice. The IGF-II positive cells are belived to be satellite
cells based on location and size. IGF-II immunoreactivity in both control and myostatin
knockout mice kidneys was localized to the epithelium of renal tubules and collecting
ducts (Fig. 7). No consistent differences in expression were noted between the two
groups of mice.
DISCUSSION
Although both IGF-I and –II are well known positive regulators of muscle
growth, their gene expressions in the current study demonstrated different patterns
between myostatin knockout and control mice muscle tissues. IGF-I mRNA levels from
soleus (predominantly red fibers), gastrocnemius (predominantly white fibers) and
pectoralis (white and red fibers) muscles were not different between myostatin knockout
and control mice (Fig. 2), while IGF-R1 mRNA levels from pectoralis muscles were
significantly higher in myostatin knockout mice than that of control mice (Fig 4). On the
other hand, IGF-II mRNA levels from soleus muscles were higher in mysotatin knockout
mice than that of control mice, while no difference was observed between myostatin
knockout and control mice gastrocnemius and pectoralis muscles (Fig. 3). Based on the
immunohistological findings of the present study, elevated IGF-II in the soleus of
myostatin knockout mice is believed to originate from strong expression of the IGF-II
gene in activated satellite cells. Varying expression patterns of IGF-I and IGF-II in
myostatin knockout mice soleus and gastrocnemius muscle could be explained as
follows. First, because myostatin mRNA and protein levels were higher in gastrocnemius
muscle (predominantly white fibers) than soleus muscle (predominantly red fibers) of
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normal adult mice (Carlson et al., 1999), complete absence of myostatin in the knockout
mice may have triggered distinct and novel muscle regulatory pathways in these two
different fiber type dominated muscles, thereby causing the observed differences in the
expression patterns of IGF-I and –II. Second, Semsarian et al. (1999) demonstrated that
myostatin mRNA level was not affected by IGF-I overexpression in C2C12 cell cultures.
Along the same line, the loss of skeletal muscle mass induced during space flight of rats
was associated with increased myostatin mRNA and protein levels in the skeletal muscle
and decreased IGF-II mRNA, while no change in IGF-I mRNA level was observed in
those rats (Lalani et al., 2000). Based upon these in vitro and in vivo findings, it is thus
possible to expect that complete absence of myostatin should increase IGF-II mRNA
levels without effecting IGF-I levels. Indeed, our finding of strong IGF-II mRNA and
protein expression in soleus muscle of myostatin knockout mice and no difference in
IGF-I mRNA levels of soleus, gastrocnemius and pectoralis muscle between these mice
partially supports the in vitro and in vivo findings. Even though no changes in either IGFI or IGF-II levels from pectoralis muscles were observed between myostatin knockout
and control mice, IGF-R1 expression from the same muscle was significantly increased
in myostatin knockout mice (Fig. 4). Because both IGFs use IGF-R1 for their mitogenic
and myogenic signal transduction pathways (for further review see, Florini et al., 1996),
increased IGF-R1 expression without corresponding increases of ligands from pectoralis
muscles of myostatin knockout mice remains to be further explored.
In the present study, strong IGF-II gene expression was observed in myostatin
knockout mice kidney, while IGF-R1 expression was significantly lowered (Fig. 3 and 4,
respectively). However, no consistent differences in IGF-II immunoreactivity were
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observed between the two groups of mice. This was not totally unexpected, since the
enzymatic immunohistochemical techniques use amplification cascades designed to
maximize chromagen precipitation resulting from low levels of antibody binding. Also,
the similar distribution of IGF-II in control and knockout mice (Fig. 7) suggests that
changes in IGF-II expression result from increased expression in cells that normally
express IGF-II rather than changes in the type of cells expressing IGF-II. Body weight of
transgenic mice overexpressing IGF-II was not different from control mice but had
increased kidney weight without any change in other organs (Wolf et al., 1994).
Although myostatin knockout kidney weight was not measured in the current and
previous studies (McPherron et al., 1997), increased IGF-II levels may have caused the
decline in IGF-R1 mRNA expression to maintain proper size of myostatin knockout mice
kidney. On the other hand, several studies suggested that metabolic actions of IGF-II,
unlike its mitogenic actions, were not mediated through IGF-R1 but through insulin
receptors, to which IGF-II can bind with low affinity (Czech, 1989, Hartmann et al.,
1992). Additionally, IGF-II, but neither insulin nor IGF-I, stimulated Na+-H+ exchange
across the brush-border membrane of proximal tubular cells (for further review, see
O’Dell and Day, 1998). Therefore, it is possible to postulate that increased IGF-II levels
from myostatin knockout mice kidneys may be due to the disturbed metabolic balance in
response to excess muscle growth of those mice. Further studies regarding the
measurements of both metabolic parameters such as, blood glucose, fatty acids, and
hormones such as insulin, growth hormone should be conducted to clarify this
speculation.
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Because of the fact that tissue samples were obtained only at one time point of
age, we do not know whether the changes in IGF-I, IGF-II and IGF-R1 gene and protein
expression were the same throughout the neonatal and adult life of the mice. Reciprocal
changes in the expression of myostatin and IGF-II and IGF-R1 may facilitate the better
understanding of not only skeletal muscle growth but also other organ development in
mammalians as well as pathophysiology of these tissues associated with disease.

76

SUMMARY
During chicken embryonic development, the growth of each tissue is regulated by
a very specific progression in the expression of genes which ultimately give rise to a
viable chicken. In first two studies of this dissertation, the developmental patterns of
genes that regulate skeletal muscle growth during embryonic development as well as
satellite cells that are responsible for postnatal skeletal muscle growth were established.
For instance, the ontogeny of myostatin gene expression in chicken embryos concurred
with time frames of primary and secondary muscle fiber formation. Also, strong
myostatin gene expression was found in the early chicken Cobb X Cobb embryos (E 0, E
1), suggesting that myostatin had a pivotal role during early chicken embryo
development, before myogenic identity was established. However, myostatin gene
expression was not detected until embryonic day 4 in Ross X Ross chicken embryos (fast
growing chicken strain, study 3), as opposed to Cobb X Cobb embryos (slow growing
chicken strain, study 1). These findings raise a question of whether myostatin has
differential role in early development in either faster or slower growing chicken lines,
even before myogenic identity is established. On the other hand, follistatin and activin-B
genes followed the same expression pattern between Ross X Ross and Cobb X Cobb
chicken embryos. Even though their expression patterns coincided partially with the
major myogenic events taking place during chicken embryonic development (see
appendix A), follistatin mRNA expression, an inhibitor of activin-B, did not exactly
follow in parallel fashion with activin-B during either Ross X Ross or Cobb X Cobb
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chicken embryo development. Based on these expression patterns, it is concluded that
follistatin actions were not simply reciprocal to those of activin-B.
Myostatin expression was almost identical in satellite cells isolated from chicken
pectoralis muscle (predominantly white fiber) and biceps femoris muscle (predominantly
red fibers), which contradicted some previous findings. As mentioned earlier, there may
be either species specific myostatin expression patterns in the two different types of
muscles or alternate posttranslational modifications of the myostatin protein occurring in
these muscles. Activin-B and follistatin expression followed parallel patterns in
pectoralis major satellite cells, whereas the same expression pattern was not observed in
biceps femoris satellite cells. Once again, these findings support the concept that
follistatin may interact with other member of the TGF-β family or other activin isoforms.
In ovo administration of rhIGF-I at embryonic day 3 resulted in enhanced skeletal
muscle growth and feed efficiency of 42-day-old broiler chickens (Kocamis et al., 1998,
2000). For a second study, we attempted to determine whether a single in ovo
administration of rhIGF-I at embryonic day 3 modified expression patterns of the
aforementioned genes resulting enhanced muscle growth and feed efficiency. As detailed
in Chapter 3, all the genes (myostatin, activin-B, follistatin, and TGF-β2) expression
patterns were, to various degrees, affected by rhIGF-I administration. Given the
complexity of the IGF system in chickens, it is difficult to identify the exact mechanism
of how these changes took place in response to a single rhIGF-I injection.
The last experiment of this dissertation was conducted in myostatin knockout
mice tissues to determine whether a correlation exists between IGFs, positive regulators
of growth, and myostatin, a negative regulator of muscle growth. As detailed in Chapter

78

4, IGF-I mRNA levels from myostatin knockout mice tissues were not different from that
of control mice. On the other hand, IGF-II mRNA levels from myostatin knockout kidney
and soleus muscles were significantly higher than that of control mice. These findings
lead us to reevaluate the concept of IGF-II involvement in growth and development of
vertebrates. First, as opposed to general belief (Baker et al., 1993), growth-promoting
actions of IGF-II in the mouse are not certainly restricted to embryogenesis. Secondly,
IGF-II, instead of IGF-I, may, at least in red muscles, be the major regulator of satellite
cell proliferation and differentiation during postnatal growth. Although these studies were
conducted with two different species, this assumption was partially supported by our
findings of strong IGF-II mRNA expression in chicken satellite cells isolated from two
different muscles, while no IGF-I gene expression was detected in either cell line. Then,
changes in gene expression patterns in response to a single in ovo rhIGF-I injection, as
detailed in Chapter 3, could be due to increased IGF-II levels in those embryos. Given the
fact that IGF-II specific receptors has not been found in chickens, IGF-I and IGF-II use
the same IGF-I type 1 receptor for their mitogenic actions. Therefore, the impact of in
ovo IGF-II administration during chicken embryonic development could be of interest.
Myostatin knockout mice showed a two- to three-fold increase in muscle mass
when compared to control, without displaying any defects in function or morphology in
skeletal muscle. Myostatin expression was inversely correlated with chronic muscle
wasting illness in humans. Thus, myostatin may impair skeletal muscle repair by
inhibiting cell replication or muscle fiber growth. It would be of interest to know whether
myostatin is required for efficient regeneration of skeletal muscles. Additionally,
identification of myostatin receptor (s), and its interaction with other TGF-β family
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recoptors would benefit a better understanding of myostatin function under normal and
diseased conditions. Furthermore, because our ultimate goal is to have more muscular,
faster-growing and leaner chickens, any attempt to modify the patterns of these muscle
specific gene expressions using various genetic techniques such as antisense
oligonucleotides or their potential inhibitors (follistatin for myostatin) to enhance muscle
growth and feed efficiency would tremendously improve the poultry and meat industry.
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Figure 1. Steady-state levels of β-actin mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n=
3) and myostatin knockout mice (n= 3) tissues. The bands for β-actin were
analyzed by densitometry and the integration values (mean ± SD) were
expressed in arbitrary units for each tissue.
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Figure 2. Steady-state levels of IGF-I mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3)
and myostatin knockout mice (n= 3) tissues. The bands for IGF-I were
analyzed by densitometry and the integration values (mean ± SD), after
normalization to β actin, were expressed in arbitrary units for each tissue.
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Figure 3. Steady-state levels of IGF-II mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3)
and myostatin knockout mice (n= 3) tissues. The bands for IGF-II were
analyzed by densitometry and the integration values (mean ± SD), after
normalization to β actin, were expressed in arbitrary units for each tissue.
Means with asterisks were significantly different (** P < 0.01).
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Figure 4. Steady-state levels of IGF-R1 mRNA in brain (B), heart (H), liver (L), kidney
(K), soleus (S), gastrocnemius (G), and pectoralis (P) muscle of control (n= 3)
and myostatin knockout mice (n= 3) tissues. The bands for IGF-R1 were
analyzed by densitometry and the integration values (mean ± SD), after
normalization to β actin, were expressed in arbitrary units for each tissue.
Means with asterisks were significantly different (* P < 0.05, ** P < 0.01).
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Figure 5. Rabbit Super Sensitive Control Serum (Biogenex, San Ramon, CA) in place of
primary antibody was used as a negative control on one section for each run.
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Control
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Figure 6. IGF-II immunohistochemistry in control and myostatin knockout mice soleus
muscles. IGF-II immunoreactivity (blue dots) was localized satellite cells.

86

Figure 7. IGF-II immunohistochemistry in control (A) and myostatin knockout mice (B)
kidneys. IGF-II immunoreactivity (blue dots) was localized to the epithelium
of renal tubules and collecting ducts.
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APPENDIX
A)

Egg Laid

Myoblast Proliferation
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Main Hypertrophy

B)

Chromatographic presentation of the myostatin RT-PCR product sequence.
Sequencing of RT-PCR products was performed as follows: First, PCR products
were cut from gels and purified using Quantum Prep Freeze’N Squeeze DNA Gel
extraction Spin Columns as outlined by the manufacturer (Bio-Rad, Hercules, CA).
Second, purified PCR products were ethanol precipitated and quantified against λ/Hind3
mass marker (Promega, Madison, WI). A pGEM-T kit was used for ligation and
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transformation reactions as described by the manufacturer (Promega, Madison, WI).
After overnight growth of individual colonies, plasmid preperation was conducted using a
QIA prep Spin Miniprep kit as outlined by the manufacturer (Qiagen, Valencia, CA).
Gene inserts were sequenced on an ABI Prism 310 Genetic Analyzer (Perkin-Elmer,
Foster City, CA).
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C)

In ovo injection procedure.
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D)
Western Blotting
Tissues from myostatin knockout mice and control mice were homogenized in 1
volume of TE (100 mM Tris, and 10 mM EDTA, pH 8.3). Subsequently, homogenates
were centrifuged at 4,000 X g for 5 minutes at 4 C. Supernatants containing proteins were
mixed with 2X sample loading buffer (125 mM Tris, 4% SDS, 20% glycerol, 10%
mercaptoethanol, 0.25% bromophenolblue, pH 6.8) and proteins were separated by SDSPAGE (120 Volt for 1.5 h., 3.75% stacking, 12% separating gels). Then, proteins were
electrophoretically transferred to nitrocellulose membrane (0.2 µm, Protran, Keene, NH)
for 1 hour at 4 C and 100 mA in buffer containing (25 mM) Tris, (192 mM) glycine, and
20% methanol in a Transblotter (Bio-Rad, Hercules, CA). Nitrocellulose membranes
were rinsed in TBS (40 mM Tris, 0.15 M NaCl, pH 7.5) for 20 minutes and then blocked
with 10% non-fat milk/TBS for 1 hour at room temperature. Membranes were then
incubated with a 1:500 dilution (as recommended by manufacturer, Sigma, St Lois, MO)
of either anti-human polyclonal insulin-like growth factor-II, insulin-like growth factor-I
receptor or insulin-like growth factor-I (Fitzgerald, Concord, MA) in 10% non-fat
milk/TBS at 4 C overnight. After washing three times for 10 minutes in 0.1% Tween 20
solution in TBS, membranes were incubated with a 1:30,000 dilution of anti-goat IgGhorseradish peroxidase conjugate in10% non-fat milk/TBS for 1 hour at room
temperature. Membranes were washed four times with 0.1% Tween/TBS solution (10
minutes each). After incubation with enhanced chemiluminescent substrate (Pierce,
Rockford, IL), antigen-antibody complexes were detected by an image analyzer (Alpha
Innotech, San Leandro, CA).
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